

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/715	A1	(11) International Publication Number: WO 93/08810 (43) International Publication Date: 13 May 1993 (13.05.93)
(21) International Application Number: PCT/US91/08204 (22) International Filing Date: 5 November 1991 (05.11.91) (71) Applicant: CARRINGTON LABORATORIES, INC. [US/US]; 2001 Walnut Hill Lane, Irving, TX 75038 (US). (72) Inventors: McANALLEY, Bill, H. ; 4921 Corn Valley, Grand Prairie, TX 75052 (US). CARPENTER, Robert, H. ; 1303 Pecan Street, Bastrop, TX 78602 (US). McDA-NIEL, Harley, R. ; 5450 Fairfield, Dallas, TX 75205 (US). (74) Agents: CHWANG, T., Ling et al.; Winstead Sechrest & Minick, 5400 Renaissance Tower, 1201 Elm Street, Dal-las, TX 75270-2199 (US).		(81) Designated States: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, PL, RO, SD, SE, SU, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published <i>With international search report.</i> <i>With amended claims and statement.</i>
(54) Title: USES OF ALOE PRODUCTS, E.G. ACEMANNAN, IN THE TREATMENT OF DISEASES REQUIRING IN-TERVENTION OF THE IMMUNE SYSTEM FOR CURE (57) Abstract Acemannan has been shown to be effective in treating a number of conditions where the principal mechanism of resolution or cure requires intervention by the patient's immune system. Acemannan has direct stimulatory effects on the immune system. Methods for treating cancer, viral diseases, respiratory and immune regulatory diseases, inflammations, infections and infesta-tions by administering an acetylated mannan derivative, such as acemannan derived from aloe, are described. The method finds use in tissue cultures, animals and plants.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TC	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

Description

USES OF ALOE PRODUCTS, E.G. ACEMANNAN, IN THE TREATMENT OF DISEASES
REQUIRING INTERVENTION OF THE IMMUNE SYSTEM FOR CURE

BACKGROUND OF THE INVENTION

5

A. Field of the Invention

The invention pertains to uses of biological response
modifying agents. More particularly, this invention relates to
the therapeutic use of a polysaccharide substance which is
predominantly an acetylated mannan or its derivatives to:

10

1) relieve the symptoms and/or cure the viral diseases of
animals, including humans, other mammals, and birds, as well
as of plants. These polysaccharidic substances inhibit viral
replication either alone, or in combination with other drugs,
either through direct antiviral effects or through their immune
stimulating activities;

15

2) enhance the response of the immune system to cancer
in humans, other mammals, animals, birds and plants. These
polysaccharidic substances stimulate immune cells of the body
and directly alter the tumor cell surface so that the stimulated
immune cells now recognize the tumor cells as "not self";

20

3) alter the body's response to antigens, toxins, allergens
and "self" antigens as seen in autoimmune diseases. These
polysaccharidic substances cause immune regulator cells to
function more appropriately to achieve homeostasis;

25

4) act as adjunctive therapy with other drugs in a wide
range of conditions where the final step in resolution or cure of
the condition requires an immune response. These
polysaccharidic substances can be used with anti-infective,
antitumor, anti-inflammatory, and antidepressant drugs with no
toxicity due to the polysaccharidic substance. The efficacy of
the combination is superior over the single drug alone.

30

**B. Description of the General Background
Information**

35

Aloe is a member of the lily family. Aloe vera contains
two major liquid sources, a yellow latex (exudate) and the clear
gel (mucilage). The dried exudate of Aloe barbadensis Miller

leaves is referred to as aloe. The commercial name is Curacao aloe. It is composed mainly of aloin, aloe-emodin and phenols. Bruce, South African Medical Journal, 41:984 (1967); Morrow et al., Archives of Dermatology, 116:1064-1065 (1980); Mapp et al., Planta Medica, 18:361-365 (1970); Rauwald, Archives Pharmazie, 315:477-478 (1982). A number of phenolics, including anthraquinones and their glycosides, are known to be pharmaceutically active. Bruce, Excelsa, 5:57-68 (1975); Suga et al., Cosmetics and Toiletries, 98:105-108 (1983).

The mucilaginous jelly from the parenchymal cells of the plant is referred to as Aloe vera gel. There are generally no anthraquinones to decompose and cause discoloration of the gel unless the gel is contaminated by an improper processing technique. Aloe vera gel is about 98.5% water by weight. More than 60% of the total solid is made up of polysaccharides of carbohydrate origin. Organic acids and inorganic compounds, especially calcium oxalate, account for the remainder of the solid.

Aloe vera was the traditional medicine of many cultures as an anthelmintic, cathartic and stomachic and was used inter alia for leprosy, burns and allergic conditions. Cole et al., Archives of Dermatology and Syphilology, 47:250 (1943); Chopra et al., Glossary of Indian Medicinal Plants, Council of Scientific and Industrial Research, New Delhi (1956); Ship, Journal of the American Medical Association, 238(16):1770-1772 (1977); Morton, Atlas of Medicinal Plants of Middle American Bahamas to Yucatan, Charles C. Thomas Publisher, 78-80 (1981); Diez-Martinez, La Zabala, Comunicado NO. 46 Sobre Recursos Bioticos Potenciales del Pais, INIREB, Mexico (1981); Dastur, Medicinal Plants of India and Pakistan; D.B. Taraporevala Sons & Co., Private Ltd., Bombay 16-17 (1962).

Aloe vera has been featured extensively in the field of dermatology, especially for treating radiation-caused skin conditions. Mackee, X-rays and Radium in the Treatment of Diseases of the Skin, 3rd Ed., Lea and Febiger, Philadelphia, 319-320 (1938); Rovatti et al., Industrial Medicine and Surgery, 28:364-368 (1959); Zawahry et al., Quotations From Medical

Journals on Aloe Research, Ed. Max B. Skousen, Aloe Vera Research Institute, Cypress, California, 18-23 (1977); Cera et al., Journal of the American Animal Hospital Association, 18:633-638 (1982). The body of scientific literature documenting medical applications in digestive problems, as a virucidal, bactericidal and fungicidal agent and in gynecological conditions is extensive and has been adequately reviewed by Grindley et al., [Journal of Ethnopharmacology, 16:117-151 (1986)].

Depending on the way the leaves are processed, mucilage and sugars are the major components of the dehydrated gel. The sugars found are galactose, glucose, mannose, rhamnose, xylose and uronic acids. Although reports conflict, the mucilage is mainly composed of mannan or glucomannan. Eberendu et al., The Chemical Characterization of Carrisyn® (in preparation); Mandal et al., Carbohydrate Research, 86:247-257 (1980b); Roboz et al., Journal of the American Chemical Society, 70:3248-3249 (1948); Gowda et al., Carbohydrate Research, 72:201-205 (1979); Segal et al., Lloydia, 31:423 (1968).

Prior to this work, the controversy over the identity of the active substance(s) in Aloe vera had not been settled. It is therefore important to clearly distinguish between the components present in the gel and those found in the exudates. A majority of the gel is a mucilage of mainly polysaccharide nature with minor amounts of various other compounds. It has been observed that in some of the activities there may be some synergistic action between the polysaccharide base and other components. Leung, Excelsa 8:65-68 (1978); Henry, Cosmetics and Toiletries, 94:42-43, 46, 48, 50 (1979). For example, several workers report that the effective components for wound healing may be tannic acid [Freytag, Pharmazie, 9:705 (1954)] and a kind of polysaccharide. Kameyama, Wound-healing compositions from Aloe arborescens extracts. Japanese Patent#7856995, (1979).

However, there are many examples in the literature indicating that polysaccharides can exhibit pharmacological and physiological activities without help from other components. Gialdroni-Grassi, International Archives of Allergy and Applied

5 Immunology, 76(Suppl. 1):119-127 (1985); Ohno et al., Chemical and Pharmaceutical Bulletin, 33(6):2564-2568 (1985); Leibovici et al., Chemico-Biological Interactions, 60:191-200 (1986); Ukai et al., Chemical and Pharmaceutical Bulletin, 31:741-744 (1983);
10 Leibovici et al., Anticancer Research, 5:553-558 (1985). One such example relates to development of atherosclerosis. Hyperlipidemia in the general population and especially in familial hypercholesterolemia is associated with coronary heart disease and death. In countries where dietary fiber intake is high, atherosclerosis appears to be uncommon. Trowell et al., Editors, Refined Carbohydrate Foods and Disease, London, Academic Press, 207 (1975). Pectin and guar are reported to lower cholesterol in normal and hyperlipidemic patients. Kay et al., American Journal of Clinical Nutrition, 30:171-175 (1977).
15 Locust bean gum, a polysaccharide composed of mannose and galactose, decreased the plasma lipoprotein cholesterol concentrations in both normal and familial hypercholesterolemic subjects. Zavoral et al., American Journal of Clinical Nutrition, 38:285-294 (1983). Addition of guar gum to carbohydrate meals decreased the postprandial rise of glucose in both normal and diabetic subjects. Jenkins et al., Lancet, 2:779-780 (1977). Kuhl et al., in Diabetes Care, 6(2):152-154 (1983) demonstrated that guar gum exhibited glycemic control of pregnant insulin-dependent diabetic patients.
20 25

 The antitumor activity of polysaccharides has been widely reported. Polysaccharides prepared from Lentinus cyathiformis are known to increase host defense against tumors. Rethy et al., Annales Immunologiae Hungaricae, 21:285-290 (1981). There are several reports that polysaccharides from mushroom, yeast or bacterial extracts can elicit a high degree of host defense activity against viral and tumor infestations. Chihara, Nature, 222:687 (1969); Shwartzman et al., Proceedings of the Society for Experimental Biology and Medicine, 29:737-741 (1932);
30 Suzuki et al., Journal of Pharmacobio-Dynamics, 7(7):492-500 (1984), also reported antitumor activity of a polysaccharide fraction (GF-1) extracted from cultured fruiting bodies of a
35

fungus, Grifola frondosa. This fraction showed equivalent, high levels of inhibiting activity when administered intraperitoneally (IP), intravenously (IV) and intratumorally (IT). However, oral administration (PO) was not effective. The GF-1 fraction also exhibited antitumor action against the solid form of Meth A fibrosarcoma and MM 46 carcinoma in mice. Lentinan, which is a 6-branched β -1-3-linked glucan similar to GF-1, was ineffective against Meth A fibrosarcoma. Chihara, "The antitumor polysaccharide Lentinan: an overview;" Manipulation of Host Defense Mechanisms; Ed. by Aoki et al., Excerpta Medica, North Holland, 1-16 (1981); Sasaki et al., Carbohydrate Research, 47(1):99-104 (1976). Synthesized branched polysaccharides were reported to demonstrate activities against tumors. Matsuzaki et al., Makromol. Chem., 186(3):449-456 (1985). Matsuzaki et al. [Makromol. Chem., 187(2):325-331 (1986)] synthesized branched polysaccharides, which showed significant activities, from ivory nut mannan (β -(1-4)-D-mannopyranose) and β -(1-4)-linked glucomannan. A partially acetylated linear β -(1-3)-D-mannan extracted from fruit bodies of Dictyophoria indusiata Fisch, also exhibited antitumor activity. Hara, Carbohydrate Research, 143:111 (1982). It appears that antitumor action depends on the type of polymer main chain and its degree of polymerization, because β -(1-3)-glucan-type polymers show higher antitumor activity than β -(1-4)-glucan and hemicellulosic polymers. Matsuzaki et al., Makromol. Chem., 187:325-331 (1986). A carboxymethylated derivative of β -(1-3)-glucan obtained from bacterial culture filtrate caused severe cell loss from established sarcoma 180 tumors within 2 hours after the injection of the derivative. Baba, Journal of Immunopharmacology, 8(6):569-572 (1986). The same author observed a compensatory increase in polymorphonuclear leukocytes due to injection of the substance. Incidentally, bestatin, a dipeptide known to possess immune-modulating and antitumor activity [Ishizuka, Journal of Antibiotics, 32:642-652 (1980)], influenced neither the tumor yield nor the polymorphonuclear leukocyte count. Baba et al., supra.

There are numerous reports on the antitumor effect of sulfated polysaccharides, including heparin [Jolles et al., Acta Univ. Int. Cancer, 16:682-685 (1960); Suemasu et al., Gann, 61(2):125-130 (1970)], sulfated laminaran and dextran [Jolles et al., British Journal of Cancer, 17:109-115 (1963)]. Yamamoto et al., in Japanese Journal of Experimental Medicine, 54:143-151 (1984), reported enhancement of antitumor activity of a fucoidan fraction by further sulfation. The sulfated product demonstrated activity against L-1210 leukemia. Polysaccharides with sulfate groups are also reported to be human T cell mitogens and murine polyclonal B cell activators. Sugawara et al., Microbiological Immunology, 28(7):831-839 (1984). Generally, homo-polysaccharides of high molecular weight with sulfate groups possess these properties. Dorries, European Journal of Immunology, 4:230-233 (1974); Sugawara et al., Cell Immunology, 74:162-171 (1982).

It has been reported that glucan extracted from the yeast Saccharomyces cerevisiae is a modulator of cellular and humoral immunity. Wooles et al., Science, 142:1078-1080 (1963). The polysaccharide also stimulated proliferation of murine pluripotent hematopoietic stem cells, granulocyte macrophage colony-forming cells and cells forming myeloid and erythroid colonies. Pospisil et al., Experientia, 38:1232-1234 (1982); Burgaleta, Cancer Research, 37:1739-1742 (1977). Maisin et al., [Radiation Research], 105:276-281 (1986) also reported that IV administration of a polysaccharide induced protection of murine hematopoietic stem cells against x-ray exposure, thereby decreasing the mortality of the mice so exposed.

Lackovic et al., [Proceedings of the Society for Experimental Biology and Medicine], 134:874-879 (1970)], took yeast cell-wall and extracted all constituent matter leaving only "mannans" that he found to be responsible for the induction of α -interferon production by monocytes. The "purified mannans" alleged to be responsible for the physiologic response had a molecular weight of 5,500-20,000 daltons.

Seljelid et al., [Experimental Cell Research], 131(1):121-129 (1981)] have observed that insoluble or gel-forming glycans

activated macrophages in vitro, whereas the corresponding soluble glycans did not. Bogwald, [Scandinavian Journal of Immunology, 20:355-360 (1984)] immobilized glycans that had a stimulatory effect on the macrophages in vitro. This led the authors to believe that the spatial arrangement of the glycan was decisive for the effect on the macrophages in vitro. A purified polysaccharide isolated from Candida albicans induced an antibody response by human peripheral blood lymphocytes in vitro. Wirz et al., Clinical Immunology and Immunopathology, 33:199-209 (1984). There were significant differences between the anti-Candida antibodies in sera of normal and Candida-infected individuals. Wirz et al., supra.

The antiviral activity of polysaccharides and polysaccharides linked to peptides has been observed. Suzuki et al., Journal of Antibiotics, 32:1336-1345 (1979). Suzuki et al., supra, reported an antiviral action of peptidomannan (KS-2) extracted from mycelial culture of Lentinus edodes. Both oral and intraperitoneal administration increased the peak serum interferon titer, which protected mice against viral infections. This was different from dextran phosphate (DP-40) [Suzuki et al., Proceedings of the Society for Experimental Biology and Medicine, 149(4):1069-1075 (1975)] and 9-methylstreptimidone (9-MS) [Saito et al., Antimier. Agent & Chemotherapy, 10(1):14-19 (1976)], which induced higher titers of interferon in mice only if administered IV or IP.

Anti-inflammatory activity of Aloe vera gel has been widely reported by both oral testimonies and respected scientific journals. Rubel [Cosmetics and Toiletries, 98:109-114 (1983)] discussed fully the possible mechanism of the anti-inflammatory effect of aloe gel. Ukai et al., [Journal of Pharmacobio-Dynamics, 6(12):983-990 (1983)] noted anti-inflammatory activity of polysaccharides extracted from the fruiting bodies of several fungi. The polysaccharides demonstrated a significant inhibitory effect on carrageenan-induced edema. One of the polymers, O-acetylated-D-mannan (T-2-HN), in addition demonstrated a more marked inhibitory

effect than phenylbutazone on scald hyperalgesia. Ukai et al., supra.

5 Other researchers have also reported anti-inflammatory effects of complex polysaccharides [Saeki et al., Japanese Journal of Pharmacology, 24(1):109-118 (1974)], glycoproteins [Arita et al., Journal of Biochemistry, 76(4):861-869 (1974)] and sulfated polysaccharides [Rocha et al., Biochemical Pharmacology, 18:1285-1295 (1969)].

10 The controversy over whether the polysaccharide is a glucomannan, mannan, pectin, or of some other composition, is resolved by a series of chemical purification steps. Yagi et al., [Planta Medica, 31(1):17-20 (1977)], using a slightly modified extraction method, isolated acetylated mannan (aloe mannan) from Aloe arborescens Miller var. natalensis. Ovodova [Khim. Prior. Soedin., 11(1):325-331 (1975)], however, earlier isolated pectin as the main component of the same aloe species.

15 The structure of these immunologically active polysaccharides and the types of structural variations appear to be the factors that control their potency and toxicity. Their mode(s) of action remain poorly understood; however, recent evidence indicates that several polysaccharides induce lymphocytes and macrophages to produce a wide range of immunologically active substances. For example, 2-keto-3-deoxy-D-manno-octulosonic acid (KDO) appears to be the
20 chemical portion of lipopolysaccharide (LPS) that provides the minimum signal for macrophage host defense activation [Lebbar et al., Eur. J. Immunol., 16(1):87-91 (1986)]. The composition of the present invention possesses all of the attributes of these immunologically active substances; it is among the most potent
25 of all known biologically active polysaccharides but differs in that no toxicity has been observed. It also manifests specific antiviral activity through alteration of viral glycoprotein synthesis.

30 A number of pharmacology studies have been conducted on Aloe vera gel in recent times. Results have included more rapid healing of radiation burns [Rowe, J. Am. Pharm. Assoc., 29:348-350 (1940)] and accelerated healing of wounds

35

[Lushbaugh et al., Cancer, 6:690-698 (1953)]. Thermal burns treated with Aloe vera gel heal much faster than untreated burns [Ashley et al., Plast. Reconstr. Surg., 20:383-396 (1957), Rovatto, *supra*, Rodriguez-Bigas et al., J. Plast. Reconstr. Surg., 81:386-389 (1988)]. The gel is useful in treating leg ulcers [El Zawahry et al., Int. J. Dermatol., 12:68-73 (1973)] and in hastening post surgical healing (Payne, Thesis submitted to Faculty of Baylor University, Waco, TX, MS Degree). Experimental evidence suggests that extracts of Aloe vera have anti-infectious properties [Solar, Arch. Inst. Pasteur Madagascar, 47:9-39 (1979)] and enhance phagocytosis [Stepanova, Fiziol. Akt. Veshchestva, 9:94-97 (1977)].

The active fraction of Aloe vera gel has been identified by Carrington Laboratories, Inc., Irving, Texas, as a long-chain polydispersed β -(1,4)-linked acetylated mannan intersperse with O-acetyl groups having a mannose monomer-to-acetyl group ratio of approximately 1:0.91. Acemannan is the nonproprietary name of the biologically active component of Carrisyn[®], a compound isolated and developed by Carrington Laboratories, Inc. See U.S. Patent No. 4,735,935, U.S. Patent No. 4,851,224, and the U.S. Patent Application Serial No. 07/229,164, and references cited therein, the disclosures of all of which are incorporated herein by reference.

Mannans, including glucomannans and galactomannans, have long been used by man. For example, galactomannans, in the form of plant gums, are widely employed as binders for control of food texture. In addition, some mannans have exhibited significant therapeutic properties (Davis and Lewis, eds. Jeanes A., Hodge J., In: American Chemical Society Symposium, Series 15. Washington, DC, American Chemical Society, 1975).

Pure mannans are relatively uncommon in higher plants, although they are a major structural component of some yeasts. For example, about 45% of the cell wall of Saccharomyces cerevisiae consists of a mannan. This mannan is a water soluble molecule composed of β -(1,6)-, β -(1,3)-, and β -(1,2)-linked, partially phosphorylated D-mannose residues [McMurrough et

al., Biochem. J., 105:189-203 (1967)]. Other biologically active mannans have been obtained from Candida utilis [Oka et al., Gann. 60:287-293 (1969), Oka et al., Gann. 58:35-42 (1968)], Candida albicans, Coccidioides immitis and Rhodotorulum rubrum [Wheat et al., Infect. Immun., 41:728-734, (1983)]. Mannans (including galactomannans and glucomannans) are relatively resistant to attack by mannosidases but can be degraded by exo- and endo-mannanases [Emi, et al., Agr. Biol. Chem., 36:991-1001 (1972), Snaith, et al., Adv. Carbohydr. Chem. Biochem., 28:401-445, (1973) Herman, Am. J. Clin. Nutr., 24:488-498 (1971), McMaster, et al., Proc. Soc. Exp. Biol. Med., 135:87-90 (1970), Jones et al., J. Biol. Chem., 243:2442-2446 (1968), Eriksson et al., Acta. Chem. Scand., 22:1924-1934 (1968)]. The most marked biological activities of mannans in mammals are activation of macrophages and stimulation of T cells. As a result, they are potent immunostimulants with significant activity against infectious diseases and tumors [Hasenclever et al., J. Immun., 93:763-771 (1964)].

Saccharomyces mannan (15 mg/kg/day) enhances carbon clearance in normal male ddI mice, presumably acting as a reticuloendothelial system stimulant [Suzuki et al., Gann. 62:553-556 (1971)]. This same mannan also increases the number of antibody-forming cells in the spleen [Suzuki et al., Gann. 62:343-352 (1971)]. In vitro studies with mouse peritoneal cells (a mixture of macrophages and lymphocytes) indicate that some mannans and mannan-protein complexes can stimulate interferon release both in vivo and in vitro [Lackovic et al., Proc. Soc. Exp. Biol. Med., 134:874-879 (1970)]. The mannans stimulated interferon release in a manner similar to endotoxins but, in contrast to endotoxins, caused minimal toxicity [Borecky et al., Acta Virol., 11:264-266 (1967), Hasenclever, supra]. The mannan from Candida albicans is active in this way, but the mannan from Saccharomyces cerevisiae is inactive [DeClercq et al., Ann. NY Acad. Sci., 173:444-461 (1970)]. Inconsistent or poor results have been obtained in other laboratories (DeClercq, supra). These differences may be due to slight structural or size differences in

the polymers [Suzuki et al., Jpn. J. Microbiol., 12:19-24 (1968)]. The latter is more likely responsible since low molecular weight mannans (5.5-20 kDa) tend to be most active in the interferon-inducing assay, also *Saccharomyces* mannan tends to be larger than *Candida* mannan.

A galactomannan of 20 kDa from *Lipomyces starkeyi* had weak interferon-inducing properties. In contrast, *Candida albicans* mannan induced the appearance of interferon activity 2-24 hrs after intravenous administration (Borecky, supra).

DMG, a degraded mannoglucan from *Microellobosporia grisea* culture fluid, can stimulate cytotoxic activities of macrophages, natural killer (NK) cells and killer T cells, and it enhances the secretion of interleukin-1 (IL-1) and colony-stimulating factors (CSF). It has more potent antitumor activity than lentinan (a glucan from *Lentinus edodes*) [Nakajima et al., Gann, 75:260-268, (1984), Inoue et al., Carbohydr. Res., 114:164-168 (1983)]. DMG stimulates macrophages to produce increased amounts of IL-1. In addition, DMG enhances 1) antibody production against sheep erythrocytes, 2) natural killer activity of spleen as well as of peritoneal cells, and 3) cytostatic activity of peritoneal macrophages [Nakajima et al., Gann, 75:253-259 (1984)].

In humans, the major mannose-binding protein is an acute-phase protein; its levels rise in stressed individuals [Ezekowitz et al., J. Exp. Med., 169:185-196 (1989)]. The envelope glycoproteins of the human immunodeficiency virus (HIV gp120 and gp41) contain mannose-rich oligosaccharides that appear to be potential ligands for the mannose-binding protein. As a result, the mannose-binding protein can inhibit HIV infection of lymphoblasts and bind selectively to HIV-infected cells. Free yeast mannan can competitively interfere with binding of this protein to infected cells. Thus, factors that induce an increase in the level of the mannose-binding protein may confer protection against HIV.

PROBLEMS TO WHICH THE INVENTION IS ADDRESSED

Virus, cancer and diseases of immune regulation continue to be major causes of both morbidity and mortality in humans,

other mammals, other animals, birds, and plants. Problems associated with currently used drugs are, namely, general toxicity, lack of efficacy (or both), deficiency in specificity and development of resistance by causative organisms or agents. Hence, better non-toxic yet therapeutically efficient agents are needed for the treatment of these diseases. Acemannan has been shown to possess a unique combination of immunodulatory and antiviral properties.

SUMMARY OF THE INVENTION

It is therefore an object to provide a method of enhancing or stimulating the immune system in an animal, comprising the administration of an amount of acetylated mannan derivative sufficient to effect the enhancement and the stimulation of the immune system in the animal.

It is also an object to provide a method of activating, inducing, and/or enhancing in an animal the synthesis and production of cytokines (such as interleukins, interferon, and prostaglandin) by monocytes and macrophages, peripheral blood adherent cells, comprising the administration of an amount of an acetylated mannan derivative to the animal sufficient to effect monocyte and macrophage activation.

It is a further object to provide a method of stimulating macrophage phagocytosis in an animal, comprising the administration of an amount of an acetylated mannan derivative sufficient to effect monocyte and macrophage activation.

It is still a further object to provide a method of producing an antiviral effect in a tissue culture, animal, or plant, comprising the administration of a sufficient amount of an acetylated mannan derivative into the tissue culture, animal, or plant to produce the antiviral effect.

It is still a further object to provide a method of producing defective virus in a human infected with virus, comprising the administration of an amount of an acetylated mannan derivative into the human sufficient to effect monocyte and macrophage activation and alter viral replication in cells infected with virus.

5 It is another object to provide a method of producing an antiviral effect in an animal, comprising the administration of an amount of an acetylated mannan derivative into the animal sufficient to induce interferon synthesis, enhance antibody formation, enhance T-cell activities, enhance killer cell activities, stimulate thymic activity, alter glycosylation of glycoprotein, alter second messenger synthesis and activity, inhibit viral replication, or a combination of any of the above.

10 It is still a further object to provide a method of producing defective virus in a master seed culture for vaccine production, comprising adding a predetermined amount of an acetylated mannan derivative into the master seed culture sufficient to produce altered viral replication.

15 It is still a further object to provide a method of stimulating and enhancing cytokine synthesis by cells of the immune system, comprising the administration of an amount of an acetylated mannan derivative into the animal sufficient to stimulate cytokine synthesis.

20 It is yet another object of the present invention to provide a method of inducing the immune system of a plant or an animal to inhibit the growth of a tumor or a cancer, comprising the administration of a sufficient amount of an acetylated mannan derivative into the plant or the animal to cause the immune system of the plant or animal to inhibit the growth of a tumor or a cancer.

25 It is also an object of the present invention to provide a method of causing the immune system of a plant or an animal to destroy or inhibit the growth of a tumor or a cancer, comprising the administration of a sufficient amount of an acetylated mannan derivative into the plant or animal to cause the immune system of the plant or animal to recognize the tumor or cancer as "not self."

30 It is a further object of the present invention to provide a method of producing anticancer effects in animals that have succumbed to cancer of viral, chemical, radiation, genetic or other origins.

35

5 It is still a further object to provide a method of producing an antitumor effect in an animal that has succumbed to tumors of genetic origins, comprising the administration of an amount of an acetylated mannan derivative into the animal sufficient to inhibit primary and secondary messenger expression of oncogenes.

10 It is yet another object to provide a method of reducing tissue damage, such as ulceration and/or necrosis, and of restoring soft-tissue capillary bed vascular perfusion in an animal, comprising the administration of an amount of an acetylated mannan derivative into the animal sufficient to restore tissue viability.

15 It is also an object to provide a method of reducing the symptoms associated with inflammatory bowel diseases in an animal, comprising the administration of an amount of an acetylated mannan derivative into the animal sufficient to reduce the symptoms associated with inflammatory bowel disease.

20 It is further an object to provide a method of reducing symptoms associated with multiple sclerosis in a human, comprising the administration of an amount of acetylated mannan derivative into the human sufficient to reduce symptoms associated with multiple sclerosis.

25 It is also an object to provide a method of reducing the symptoms associated with neurochemical disorders and depression in an animal, comprising the administration of an amount of acetylated mannan derivative into the animal sufficient to reduce the symptoms associated with neurochemical disorders and depression.

30 It is a further object to provide a method of treatment of acute and chronic autoimmune disease in an animal, comprising the administration of an acetylated mannan derivative into the animal sufficient to cause immunosuppression and/or immunomodulation of the cells and tissues responsible for the autoimmune disease.

35 It is still a further object to provide a method of causing a more rapid healing of traumatic injuries in an animal,

comprising the administration of an acetylated mannan derivative into the animal sufficient to cause the animal's body tissue repair mechanism and immune system to respond more rapidly and appropriately to a trauma.

5 It is a further object to provide a method of causing an affect on the respiratory system of an animal to ameliorate the symptoms associated with asthma, conjunctivitis, rhinitis and bronchitis, comprising the administration of an acetylated mannan derivative into the animal sufficient to cause
10 immunomodulation of the cells and tissues responsible for the symptoms associated with asthma, conjunctivitis, rhinitis and bronchitis.

 It is still a further object to provide a method of producing a prophylactic effect in an animal resulting in the
15 prevention of infection by infectious organisms, comprising administration of an acetylated mannan derivative into the animal sufficient to cause the animal body's immune system to prevent infection by an infectious organism.

 It is also an object to provide a method of reactivating enzyme systems and organ systems to cause a return to
20 function of age-depleted tissue, comprising the administration of an acetylated mannan derivative into the animal sufficient to cause the animal body and its tissue to produce cell products and up-regulate genes which cause the tissue to return to
25 function and express juvenile cell function and characteristics.

 It is a still further object to provide a method of immunoenhancing vaccines by the production of an adjuvant effect, comprising adding a predetermined amount of an acetylated mannan derivative into the vaccine product.

30 It is a still further object to provide a method of treating an animal afflicted with a tumor, comprising administration to the animal an amount of an acetylated mannan derivative sufficient to effect monocyte and macrophage activation and enhance natural killer cell activity and specific tumor cell lysis
35 by cytotoxic cells and/or antibodies.

 It is a still further object to provide a method of introducing an acetylated mannan derivative into the cellular

organelles of (i) a noninfected cell to give rise to altered glycoproteins which provide said cell with protection from viral infection and/or of (ii) a virus-infected cell to produce glycoproteins which destroy or inhibit viral expression in said infected cell, comprising introducing a sufficient amount of an acetylated mannan derivative into the cell to alter viral glycoproteins in or at the surface of the cell.

It is still a further object to provide a method of introducing an acetylated mannan derivative into the cellular organelles of a virus-infected cell to produce glycoproteins which prevent or inhibit viral expression in said infected cell wherein the acetylated mannan derivative is introduced into the cell in an amount sufficient to render the virus noninfective.

It is a still further object to provide a method of introducing an acetylated mannan derivative into the cellular organelles of a virus-infected cell to produce altered glycoproteins which prevent or inhibit viral expression in said infected cell wherein the cell is virus-infected, comprising the administration of the acetylated mannan derivative into the cell in an amount sufficient to (i) to cause a broad spectrum of specific antibodies to be produced which provide a broader immunological response than the cell had prior to introduction, and (ii) to enhance the rate of broad spectrum antibody production.

It is also an object of this invention to provide a method of increasing, in an animal, amounts of acetylated mannan derivative to intra- and extra-cellular metabolic pathways to correct malabsorption and mucosal cell maturation syndromes in an animal, comprising the step of administration to the animal an amount of the acetylated mannan derivative sufficient to provide additional acetylated mannan derivative for the synthesis of glycoprotein thus accelerating Michaelis-Menten (K_m) kinetics for mannosyl transferase activity.

It is a further object to provide a method of inducing a virus-infected mammalian cell to express altered viral glycoprotein antigens on its surface which will initiate an antibody-dependent cell cytotoxicity (ADCC) by cytotoxic

lymphocytes, comprising administration to the mammal an amount of an acetylated mannan derivative into the infected cell sufficient to produce altered viral glycoproteins and to cause the altered viral glycoproteins to be expressed on the surface of the infected cells and thus expose them to humoral antibodies.

It is still another object to provide a method of introducing an acetylated mannan derivative into a human to reduce the symptoms associated with multiple sclerosis, comprising administration to the human an amount of the acetylated mannan derivative sufficient to reduce plaque formation and to induce plaque replacement with functional tissue in the central nervous system cells.

It is also an object to provide a method of introducing an acetylated mannan derivative into a mammal to reduce the symptoms associated with inflammatory bowel disease, comprising the administration to the mammal an amount of the acetylated mannan derivative sufficient to resolve lesions associated with inflammatory bowel disease by increasing tissue regeneration of ulcers in said lesions and by reducing autoimmune immunoglobulin in local tissues of said lesions.

DESCRIPTION OF THE FIGURES

Fig. 1 shows synergistic antiviral effects of acemannan and AZT on the viability of HIV-infected MT-2 cells.


5 Fig. 2 shows synergistic antiviral effects of acemannan and AZT as quantified by the percent increase in viability of HIV-infected MT-2 cells.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

10 Carrisyn® is the brand name given by the assignee of the instant invention to the purified ethyl alcohol extract of the inner gel of the leaves of Aloe barbadensis Miller. The active component of Carrisyn® has been designated "acemannan" by the United States Adopted Name Council. Not less than 73% of Carrisyn® extract is acemannan; Carrisyn® extract comprises generally about 73% to 90% acemannan. Carrisyn® extract is
15 generally produced by removing the outer sheath of the leaf, then removing and processing the inner filet or mucilage as follows: pH adjustment, ethanol extraction, freeze drying and grinding. See U.S. Application Serial No. 144,872 filed January 1988, a continuation-in-part of U.S. Application Serial No. 20 869,261 (now U.S. Patent No. 4,735,935), the disclosures of all of which are incorporated herein by reference. Processing in this manner predicts that essentially no covalent bonds are altered and therefore no toxic compounds are created. These manufacturing steps were developed to overcome the inability
25 of traditional aloe product producers to standardize and stabilize the polysaccharides.

Carrisyn is a fluffy, white, amorphous powder, which is poorly soluble in water and dimethyl sulfoxide and insoluble in most other organic solvents. This powder contains not less than
30 73% of a polysaccharide consisting essentially of linear B(1-4)-D-mannosyl units. The polysaccharide is a long chain polymer interspersed randomly with acetyl groups linked to the polymer through an oxygen atom. The generic name for the polymer is acemannan. The degree of acetylation is approximately 0.91
35 acetyl groups per monomer as determined by the alkaline hydroxamate method. See Hestrin, Journal of Biological Chemistry, 180:240-261 (1949). Neutral sugars linkage

analysis indicates that attached to the chain, probably through an $\alpha(1-6)$ linkage, is a D-galactopyranose in the ratio of approximately one for every 70 sugars. The 20:1 ratio of mannose to galactose indicates that galactose units are also linked together, primarily by a $\beta(1-4)$ glycosidic bond. The chemical structure of acemannan may be represented as follows:



General Structure of Ultrapure Acemannan

DEFINITION OF TERMS

The term "virus" as used herein includes both the DNA and the RNA virus. It can either be an enveloped or a non-enveloped virus. The term "enveloped virus" in all cases but one is understood to mean a virus encased within a modified host cell membrane; the poxviruses produce their own envelope. Typical enveloped viruses are set forth in Table 1.

TABLE 1

5 The following are enveloped viruses as divided into family and
common species or genus:

	<u>Family</u>	<u>Common Species or Genus</u>
	Herpesviridae	human herpes simplex virus types I & II
10		bovine mammillitis virus
		herpes B virus of monkeys
		pseudorabies virus
		equine rhinopneumonitis virus
		varicella-zoster virus
15		human cytomegaloviruses
		murine cytomegaloviruses
		Epstein-Barr virus
		Baboon herpes virus
		Chimpanzee herpes virus
20		Marek's disease herpes virus
		Hinze virus
		Turkey herpes virus
		Herpes virus ateles
		Herpes virus saimiri
25		Infectious bovine rhinotracheitis virus
	Iridoviridae	African swine fever virus
		Frog virus group (Ranavirus)
		Iridovirus
30		Chloriridovirus
	Poxviridae	vaccinia virus
		smallpox virus
		cowpox virus
35		monkeypox virus
		buffalopox virus
		camelpox virus

- ectromelia of mice virus
rabbitpox virus
Orf virus
avipox virus
5 sheep-pox virus
goatpox virus
lumpy skin disease (Neethling) virus
myxoma virus of hares
fibroma viruses of rabbits
10 fibroma viruses of squirrels
swinepox virus
Yaba monkey virus
molluscum contagiosum virus
- 15 Hepadnaviridae human hepatitis B virus (HBV)
woodchuck hepatitis virus
ground squirrel hepatitis virus
duck hepatitis virus
- 20 Orthomyxoviridae Influenza virus, types A, B, and C
- Paramyxoviridae Newcastle disease virus of fowl
human parainfluenza viruses
Sendai virus
25 mumps virus
paramyxoviruses
measles virus
rinderpest virus of cattle
canine distemper virus
30 peste-des-petits-ruminants virus
of sheep and goats
respiratory syncytial virus of man
bovine respiratory syncytial virus
pneumonia virus of mice
35

	Rhabdoviridae	rabies virus
		vesicular stomatitis virus of:
		horses, cattle and swine
5		chandipura virus
		lyssavirus
		duvenhage virus
		Lagos bat virus
		mokola virus
10	Bunyaviridae	bunyavirus (Bunyamwera, Bwamba, California, Capim, Guama, phlebovirus koongol, patois, simbu and tete viruses)
		sandfly fever virus
		Rift Valley fever virus of sheep and
15		ruminants
		Nairovirus
		Crimean-Congo hemorrhagic fever viruses
		Uukuvirus
		Uukuniemi virus
20		Hantaan virus
		Korean hemorrhagic fever virus
	Filoviridae	ebola virus
		Marburg virus
25		
	Nodaviridae	Nodamura virus
	Togaviridae	Alphaviruses
		aura virus
30		Chikungunya virus
		eastern equine encephalitis virus
		getah virus
		mayaro virus
		middleburg virus
35		mucamba virus
		ndumu virus
		O'Nyong-nyong virus

- pixuna virus
ross river virus
semliki forest virus
sindbis virus
5 una virus
Venezuelan equine encephalitis virus
western equine encephalitis virus
Whataroa virus
rubella virus
10 mucosal disease virus
border disease virus
hog cholera virus
- Flaviviridae flavivirus
15 Brazilian encephalitis virus
Bussuquara virus
dengue virus
iiheus virus
Israel turkey meningoencephalitis virus
20 Japanese B encephalitis virus
kunjin virus
Kyasanur forest disease virus
langat virus
louping ill virus
25 modoc virus
Murray valley encephalitis virus
ntaya virus
omsk hemorrhagic fever virus
powassan virus
30 St. Louis encephalitis virus
spondwnei virus
tick-borne encephalitis
Uganda S virus
US bat salivary gland virus
35 wesselsbron virus
west nile fever virus
yellow fever virus

zika virus
European tick-borne encephalitis
Far Eastern tick-borne encephalitis virus
Russian tick-borne encephalitis

5

Retroviridae type C oncovirus group

type B oncovirus group

type D retrovirus group

avian complex leukemia virus

10

Rous sarcoma virus

murine complex leukemia virus

mouse sarcoma virus

murine mammary tumor virus

feline leukemia complex virus

15

feline sarcoma complex virus

woolly monkey sarcoma virus

gibbon leukemia virus

Mason-Pfizer virus

hamster leukemia virus

20

rat leukemia virus

bovine lymphoma virus

human T cell leukemia viruses:

types 1 and 2 etc.

spumaviridae: syncytial and foamy

25

viruses of humans, monkeys, cattle, cats

visna virus of sheep

Maedi virus

progressive pneumonia viruses of sheep

*human immunodeficiency viruses:

30

(include HTLV III/LAV) HIV, HTLV IV,
LAV-2, STLV-III_{AGM}

Arenaviridae

Junin virus

lassa virus

35

machupo virus

pichinde virus

lymphocytic choriomeningitis virus

25

lassa fever virus
 arenavirus

Other virus-like agents

5

viroids-prions

kuru virus

Creutzfeldt-Jakob disease virus

scrapie virus

transmissible mink encephalopathy

10

Aleutian disease of mink

bovine spongiform encephalopathy "virus"

*NOTE:

under Retroviridae

human T-lymphotropic virus type III

15

(HTLV-III)

Lymphadenopathy virus (LAV)

human immunodeficiency virus (HIV)

simian T-lymphotropic virus type III

(STLV-III_{AGM})

20

human T-lymphotropic virus type IV

(HTLV-IV)

(HTLV III and LAV are now usually
 referred to as HIV).

25

The term "tumor" as used herein includes both malignant and non-malignant neoplasms including tumors of viral, chemical, radiation, genetic and other origins. It can be of embryonic ectodermal origin, embryonic mesodermal origin, or embryonic endodermal origin. It can be from the embryonic surface ectoderm, the embryonic neuroectoderm, the embryonic head mesoderm, the embryonic paraxial mesoderm, the embryonic intermediate mesoderm, the embryonic lateral mesoderm, or the embryonic endoderm. Thus, tumors in an animal include: tumors of the skin and soft tissues; tumors of the muscle; tumors and tumor-like lesions of joints and adjacent soft tissues; tumors of bone and cartilage; tumors of the lymphoid and hematopoietic tissues; tumors of the respiratory

30

35

system; tumors of the alimentary tract; tumors of the liver, gall bladder and pancreas; tumors of the urinary system; tumors of the genital systems; tumors of the mammary gland; tumors of the endocrine glands; and tumors of the nervous system and eye.

5 Human malignant tumors include: acute lymphoid leukemia; acute myeloid leukemia; chronic myeloid leukemia; chronic lymphoid leukemia; polycythemia vera; myelosclerosis with myeloid metaplasia; multiple myeloma; primary
10 macroglobulinemia; Hodgkin's disease; non-Hodgkin's lymphoma; skin cancer; malignant melanoma; head and neck cancer; lung cancer; gastrointestinal cancer; breast cancer; gynecologic cancer; trophoblastic disease; testicular cancer; prostate cancer; renal carcinoma; bladder cancer; endocrine
15 tumor; brain tumor; retinoblastoma; neuroblastoma; Wilm's tumor; osteogenic sarcoma; Ewing's sarcoma; and soft-tissue sarcoma.

The term "microorganism" as used herein includes parasites, bacteria, and other organisms and agents causing
20 infestation. Parasites include arthropod parasites, helminth parasites, protozoal parasites, and hemaprotzoal parasites. Examples of these parasites include demodex mange, hookworm and coccidia.

The term "glycosylation" means the addition of
25 carbohydrate molecules to a protein molecule. An acetylated mannan derivative, in particular acemannan, may exert its therapeutic effect by two possible mechanisms. One is the altering of glycosylation, such as inhibition of glucosidase I or the incorporation of the acetylated mannan derivative into
30 glycoprotein. The other possible mechanism is enhancement of the antigenicity of the virus or the tumor, or the enhancement of immunocompetency of the host. The enhancement of antigen can be achieved through the presentation by macrophage; reception by T or B cells or both, altered antigen presentation,
35 or adjuvant effect. In a sense, acetylated mannan derivative enhances the recognition of a tumor or of an infectious agent,

such as a virus or another microorganism, as "not self" by the host.

5 The administration of acetylated mannan derivative can be achieved by topical application, oral ingestion, IP route, IV route or other parenteral routes of administration.

Not only can the acetylated mannan derivative be given to the recipient as a single agent, it can also be used in combination with other known therapeutic agents that are characterized by their requirement of the participation or aid of the host's immune system to achieve their maximal therapeutic effect.

10 Acemannan has now been discovered to be a potent inducer of IL-1 and prostaglandin E2 (PGE2) production by human peripheral blood adherent cells in culture. The instant invention is believed to be the first practical non-toxic stimulator of IL-1 release. IL-1 is an important macrophage product reported in the literature to influence the activity and production of lymphocytes, fibroblasts, B-lymphocytes and endothelial cells. See Old, Scientific American, 258(5):59-60, 69-75 (1988).

15 IL-1 induces fibroblast proliferation which is fundamental to wound healing. IL-1 also: (1) enhances bone marrow activity; it may be therapeutic in individuals whose bone-marrow is depressed; and (2) enhances the immune system in general.

25 A series of experiments with mixed lymphocyte cultures (MLC) has shown that acemannan increases the alloantigenic response of these lymphocytes in a dose-related fashion. Incubation of acemannan with monocytes permitted monocyte-driven signals to enhance the T lymphocyte response to lectin. Related studies on acemannan's effects on MLC have shown an increase in phagocytosis and activity of natural killer cells. Thus, in these in vitro test systems, acemannan is non-toxic and is an immunoenhancer.

30 Acemannan actively stimulates lymphocytes to secrete lymphokines and also causes HIV-infected lymphocytes to produce altered glycoproteins (GP-120) by a mechanism similar

to that of glucosidase I inhibitors. See Gruters et al., Nature 330:74-77 (1987) and Pal et al., Interviol. 30:27-35 (1989). Acemannan is phagocytized and apparently pumped to the Golgi/glycoprotein apparatus of the monocyte where it interferes directly with glycoprotein synthesis.

A. Toxicology

The toxicological effects of acemannan have been studied in both in vivo and in vitro systems. Acemannan is not mutagenic or blastogenic in in vitro test systems. In vitro, the compound was non-toxic for H-9, MT-2 and CEM-SS lymphoid cells. In vivo toxicology studies on acemannan include a 91-day subchronic oral toxicity study in dogs, a 180-day chronic oral toxicity study in rats and an 180-day chronic oral toxicity study in humans. In these studies, no toxic effects were noted in dogs receiving up to 825 mg/kg of acemannan per day for 91 days. No clinical, gross pathologic or toxic effects were noted in rats receiving up to 38,475 ppm acemannan in their feed for 180 days. No adverse clinical or toxic effects were noted in human patients receiving 800 mg per day of acemannan for 180 days.

In pilot studies, administration of acemannan to dogs caused an absolute monocytosis in blood samples taken for complete white blood cell counts and morphology differential. Within 2 hours after oral administration of high doses of acemannan, large activated monocytes appeared in circulation. A similar effect has been observed in humans.

A study was performed using human peripheral blood monocyte cell cultures and ¹⁴C-labeled acemannan to track the incorporation or absorption of acemannan into a biological system. In this study, detectable amounts of ¹⁴C-labeled acemannan were absorbed or ingested by human peripheral monocyte/macrophage cells. Peak incorporation occurred at 48 hours. At a concentration of 5 mg/ml, the ¹⁴C-labeled acemannan was not cytotoxic to the monocyte/macrophage cells, and the weight/volume (w/v) digested cell mass was 760 times greater than the w/v of the digested acemannan solution. These results suggest that the macrophage is capable of

maintaining intracellular concentration of acemannan at very high levels that are not cytotoxic.

5 A pyrogen assay was performed in rabbits in accordance with the pyrogen test protocol outlined in the U.S.P. XXI, Biological Test [151], using a 1 mg/ml injectable solution of acemannan. More frequent temperature measurements were taken than specified in the U.S.P. because of the unknown systemic effects of injected acemannan. Temperature changes in test animals did not exceed minimum changes allowed by the U.S.P. protocol; therefore, the solution met the U.S.P. requirements for absence of pyrogens. Acemannan injectable elicited a maximum body temperature increase of 0.3°C in one rabbit. This temperature rise occurred 90 minutes after injection. Acemannan is an inducer of IL-1 secretion by macrophages and monocytes in vitro. Since IL-1 is a potent pyrogen, this might explain the minimal, delayed temperature rise in this rabbit.

20 Twenty-four human subjects enrolled in and completed the study of the safety and tolerance of orally-administered acemannan. Clinical laboratory results showed that shifts out of the normal range occurred in the following: CO₂ in seven subjects, cholesterol in three subjects, triglycerides in two subjects, phosphorous in one, hemoglobin in four, basophils in two, monocytes in three, eosinophils in three, lymphocytes in four, neutrophils in two, and one each in red and white blood cells. Small numbers of red and white blood cells were also found in the urine. None of these shifts was clinically relevant.

25 Immune profile results showed group differences between Day 1 to Day 7 values for the following: CD-16, CD-4 (T-4), CD-8+Leu7, CD-4+CD-25, CD-8+CD-16, Leu7 and TQ-1. Mitogen responses were in the low range.

30 Vital signs did not appear to exceed normal ranges. There were no group differences in urine output. One subject in Group IV had diarrhea and loose stools during the study. One subject in Group I had loose stools during days 2 to 4 of the study. A total of 5 subjects reported a total of eight adverse events. All

the events occurred in subjects receiving 1600 or 3200 mg oral acemannan daily for 6 days.

B. Mode of Administration

5 The physical properties of acemannan allow it to be formulated and incorporated into all pharmaceutical dosage forms known to those skilled in the art. The biopharmaceutical and toxicological properties of acemannan permit it to be used in tissues and organs of living organisms and to be administered over a wide range of doses.

10 Acemannan may be administered to an animal orally, parenterally, topically and locally, in a daily dosage of 0.001 mg/kg to 1000 mg/kg body weight per day.

15 Mixed with suitable auxiliaries, acemannan may be compressed or filled into solid dosage units such as pills, tablets and coated tablets, or it may be processed into capsules. These oral dose forms would be administered at a dosage of about 0.1 mg/kg to 1000 mg/kg of body weight per day.

20 By means of suitable liquid vehicles, acemannan can be injected in solutions, suspensions or emulsions. These products would be administered at a rate of 0.001 mg/kg to 1000 mg/kg of body weight per day. As an adjunctive component of a vaccine or other product, acemannan would be used at a rate of 0.001 to 1000 mg per unit dose of adjuvanted product.

25 Topical administration of acemannan can be in the form of a processed gel, cream, lotion, solution, ointment or powder. These formulations could contain up to 90% acemannan.

Example 1

PRODUCTION OF INTERLEUKIN-1 AND PGE2 BY HUMAN ADHERENT PERIPHERAL BLOOD LEUKOCYTES 30 STIMULATED WITH ACEMANNAN

A. Induction of IL-1 Production

35 Human mononuclear cells were separated from heparinized whole blood by density-gradient centrifugation in Ficoll-Hypaque (Pharmacia, Sweden). After washing, cells were resuspended at a concentration of 2×10^6 cells/ml in RPMI-1640 with 25 mM Hepes, and supplemented with 50 U/ml penicillin, 50 µg/ml streptomycin and 2 mM L-glutamine. Two

ml aliquots of the cell suspensions were dispensed into each well of a six-well plate and incubated for 1 hour at 37°C in a 5% CO₂-humidified atmosphere. After removal of nonadherent cells, adherent cells were washed three times with the medium described above. Two ml of medium supplemented with 5% pooled human AB serum were added to each well. Cultures were stimulated with acemannan at different concentrations. Simultaneous controls with lipopolysaccharide (LPS) from *E. coli* (Sigma 0111:B4) at a final concentration of 20 µg/ml, and without any addition (background), were included. The cultures were incubated at 37°C as described above for 24 hours. Supernatants were harvested, centrifuged to remove cells, and dialysed against 500 volumes of PBS for 48 hours (changed once), followed by 4 hours of dialysis against 20 volumes of RPMI-1640 with 25 mM Hepes, antibiotics and L-glutamine as described. Supernatants were frozen at -20°C until IL-1 activity was evaluated.

B. IL-1 Determination in Supernatants

Two different procedures were used to assay IL-1: (1) the thymocyte proliferation assay and (2) an ELISA assay specific for IL-1.

1. Thymocytes from C₃H/HeJ mice 5-8 weeks old were used. A homogeneous cell suspension was prepared in minimum essential medium (MEM) supplemented with 5% FCS, 100 U/ml penicillin, 50 g/ml streptomycin, 2 mM L-glutamine and 5 x 10⁻⁵ M 2-mercaptoethanol. The cell concentration was adjusted and dispersed into 96-well plates at 1 x 10⁶ cells/well. Phytohemagglutinin (PHA) was added to each well at a concentration of 10 µg/well. Samples were diluted serially and a volume of 25 µl was added to each well, starting from 1:10 to the final dilution. Every dilution was tested in quadruplicate. Plates were incubated at 37°C in a humidified atmosphere with 5% CO₂ for 72 hours and were pulsed with [³H]-thymidine (0.5 µCi/well) during the last 16 hours. Cells were harvested onto fiberglass filters with an automatic cell harvester, and radioactivity was measured by standard scintillation procedures. Results are represented as cpm of thymidine

incorporation by thymocytes in response to the supernatants at a final 1:10 dilution.

2. Two-site "Sandwich" ELISA for IL-1. This procedure has recently been described in Journal of Immunology, 138:4236 (1987), the disclosure of which is hereby specifically incorporated herein by reference. See also U.S. Patent No. 3,654,090 and U.S. Patent No. RE 31,006 to Schuurs et al. Briefly, monoclonal purified antibody IL-1-H6 against IL-1 β , (100 μ l/well, 10 μ g/ml) was coated on vinyl assay plate wells overnight at 4°C. The wells were washed with PBS/0.5% Thimerosal and countercoated with 200 μ l of 5% non-fat dry milk/0.5% Thimerosal/PBS for 1 hour at room temperature. After washing, 50 μ l/well of sample or human recombinant IL-1 standard and 50 μ l of another monoclonal antibody against a non-overlapping epitope of IL-1, [biotinylated IL-1 β -H67 (2 μ g/ml) in 1% non-fat dry milk/0.5% Thimerosal/PBS], were added, and the plates were incubated for 2 hours at room temperature. After washing, 100 μ l/well of a 1:1000 dilution of streptavidin-peroxidase were added and the plate was incubated for 1 hour. The wells were washed, incubated for 30 minutes in the dark with 100 μ l OPD substrate solution, and absorbance at 450 nm was measured.

C. Determination of PGE₂

PGE₂ was evaluated with a radioimmunoassay in the same non-dialyzed supernatants. The antibody to PGE₂ (ICN Biomedical, Inc., Costa Mesa, CA) was used according to the manufacturer's instructions, which are incorporated herein by reference.

D. Observations

Representative experiments are shown in Table 2. Acemannan is a potent inducer of IL-1 production by human adherent peripheral blood leukocytes. At doses between 1 and 10 μ g/ml, acemannan extract induced production of IL-1 comparable to that induced by 20 μ g/ml LPS, which is the reference inducer of IL-1 production. Acemannan in the same dose range also induced the production of PGE₂ at levels comparable to those induced by 20 μ g/ml LPS (positive control).

Table 2

**INDUCTION OF PGE₂ SYNTHESIS BY HUMAN PERIPHERAL
BLOOD ADHERENT CELLS STIMULATED BY ACEMANNAN
AND BY LIPOPOLYSACCHARIDE (LPS).**

	Experiment No.	Stimulator	PGE ₂ (ng/ml)
	198	0	0
		LPS 20 µg/ml	2.6, 3.9
10		Acemannan 10 µg/ml	3.5
		Acemannan 1 µg/ml	0
	148	0	0
		LPS 20 µg/ml	0.5, 1.3
15		Acemannan 10 µg/ml	0.7

**Example 2
EFFECT OF ACEMANNAN ON
PHAGOCYTOSIS IN VITRO**

20 The effect of acemannan was studied in vitro to ascertain
its effect on phagocytic function. CBA mice were injected IP
with 1 mg/kg acemannan, and peritoneal and splenic
macrophages were collected 3 days later. Thioglycolate and
saline were similarly tested as positive and negative controls,
25 respectively. The macrophages were incubated with sheep red
blood cells (SRBC) as ingestion particles in the presence and
absence of anti-SRBC titers, and phagocytosis was measured
histologically as percent cells that ingested SRBC. Although non-
specific phagocytosis was increased slightly after acemannan
30 treatment, phagocytosis was significantly increased in the
presence of antibody. In the presence of complement,
acemannan-stimulated, antibody-mediated phagocytosis was
increased to an even greater extent. These results indicate that
acemannan may increase the number of macrophages and
35 enhance their phagocytic activity. Such responses may
contribute to acemannan's effectiveness as a stimulant of
wound healing and as an anti-infectious agent.

A. Methods and Materials

Acemannan was stored at room temperature in its dried form. The amount needed for each experiment was weighed out and microwaved in 2-minute exposures at 600 watts of power. It was then transferred to a sterile plastic centrifuge tube and microwaved for 1 additional minute. The material was diluted in cell culture medium (RPMI-1640) to the desired concentration.

Phagocytic Cells: Mouse spleen cells were obtained from BALB/c mice purchased from Harlan Sprague-Dawley. The mice were killed by CO₂ asphyxiation, and their spleens were removed aseptically. Subsequently, the cells were separated into adherent and non-adherent populations by nylon wool column fractionation according to the method of Journal of Immunology, 71:220, the disclosure of which is hereby specifically incorporated by reference. Adherent cells were determined by microscopic analysis, as described below, to be macrophages (monocytes) and lymphocytes in a ratio of 4 to 1. After single-cell suspensions were obtained by monolayer disruption, both adherent and non-adherent single cell preparations were placed on ficoll-hypaque and centrifuged to obtain a mixture of lymphocytes and macrophages.

Blastogenesis Assay: A standard blastogenesis assay was set up as outlined below. The mitogen used in the assay was PHA-P obtained from Burroughs Wellcome. As indicated for individual experiments, the cultures were maintained for 72 hours in a 5% CO₂, humidified atmosphere. Tritiated thymidine was added during the last 6 hours of the culture. Cell concentrations per well, using flat bottom microtiter tissue culture plates, were 5×10^5 mouse cells/0.2 ml. Cells were deposited in the wells and acemannan or mitogen was added. A stimulation index (SI) was calculated using the formula:

$$SI = \frac{\text{cpm experimental} - \text{cpm background}}{\text{cpm control} - \text{cpm background}}$$

Cell Staining: Briefly, smears of cells were stained by non-specific esterase stain as follows. Approximately 2×10^6 cells in 2 drops were mixed with 2 drops of fetal calf serum and 4 drops of a fixative solution consisting of a mixture of 25 ml of 35% formaldehyde, 45 ml of acetone, 100 mg of KH_2PO_4 , 10 mg of Na_2HPO_4 and 30 ml of water. The slides were incubated with a mixture of 10 mg of naphthyl acetate and 4.5 mg of Fast Blue stain in 1.4 ml of ethylene glycol monomethyl ether with 5 ml of 0.1 M Trismaleate buffer, pH 7.8 (Wright's stain). The stain was allowed to react for 10 minutes, then washed in water for 20 seconds. A counterstain of 0.2 g of Giemsa stain, 12.5 ml of ethanol and 12.5 ml of glycerol was used for 30 seconds before washing again.

Induction of Peritoneal Macrophage Cells: Saline thioglycolate broth (1 mg/kg) or acemannan (1 mg/kg) was injected IP into female BALB/c mice to induce peritoneal exudate macrophage cells. Induced cells were removed from the peritoneal cavity 3 days post-injection.

Macrophages were washed twice with phosphate-buffered saline (PBS) and covered with 2 ml of fresh medium; 0.1 ml of the macrophage suspension was added to each tube. Cultures were placed for 30 to 60 minutes into a 37°C , humidified 5% CO_2 -95% air incubator. Cultures were washed twice with PBS and covered with 2 ml of PBS. One of each pair of coverslips was removed with needle-nosed forceps, dipped for 5 seconds only in distilled water, and promptly replaced in the culture dish. The PBS was removed, and the cultures were covered with ice-cold glutaraldehyde. After 10 minutes, the glutaraldehyde was removed, and the coverslips were overlaid with distilled water.

Mounted coverslips were examined promptly with the oil immersion lens of a phase contrast microscope. Attachment was scored on the coverslip that was not subjected to hypotonic shock, whereas ingestion was scored on the coverslip that was lysed in distilled water.

Antibody-Dependent and Antibody-Independent Phagocytosis: SRBC, obtained from Austin Biologics Laboratory,

Austin, Texas, were washed three times in PBS (pH 7.2). BALB/c mice were given IP injections of 10^6 cells and bled on day 14 post-injection. Serum was collected, pooled and heat inactivated at 56°C for 45 minutes. Agglutination titers were determined to be 1024 using round-bottomed microtiter wells.

Antibody-independent phagocytosis was determined by incubation of SRBC (0.5% v/v) with macrophages (10^6) in RPMI-1640 containing 20% fetal calf serum (FCS). Slides were prepared at various intervals and stained. The percent macrophages that had ingested red cells was determined visually by counting 200 cells/slide and three slides/animal.

Antibody-dependent phagocytosis was determined using SRBC (0.5% in RPMI-1640 with 20% FCS) mixed with anti-SRBC serum or IgM fraction (minimum titer of 2000). The mixture was incubated for 15 minutes at 37°C, then washed twice in PBS (pH 7.2) and resuspended to the original volume.

Serum Fractionation: Whole serum was fractionated to remove IgM by euglobulin precipitation and dialysis against distilled water. After dialysis at 4°C for 24 hours, precipitate was removed by centrifugation at 1500 x G for 20 minutes, and supernatant was analyzed by ion electrophoresis and complement-mediated lysis. Less than 5% of the original IgM remained.

B. Results

To evaluate the effect of acemannan on macrophages, the first experiment utilized mouse spleen cells cultured in vitro with acemannan (Table 3).

Table 3

**PERCENT CELL TYPES BY HISTOLOGICAL
EVALUATION OF MOUSE SPLEEN CELLS IN CULTURE**

Time in Culture	Cells(a)	<u>Acemannan (μg/well)</u>			
		0.0	0.002	0.02	0.2
72 hours	macrophages	30±6	32±7	41±3	45±9
	lymphocytes	70±5	68±8	59±3	55±6
96 hours	macrophages	22±4	28±4	36±6	38±8
	lymphocytes	78±8	72±7	64±10	62±4

(a) Macrophages (monocytes) were determined by esterase staining. The results are expressed as mean ±S.D. The results are from six experiments with 200 cells studied/experiment. "Lymphocytes" are cells that did not stain by esterase and had the appearance of lymphocytes by Wright's stain.

Cultures were incubated for 72 or 96 hours, and at termination of the experiment smears were made and stained by Wright's stain and by the esterase method. The relative percentage of macrophages and lymphocytes was determined. At 72 hours there was a dose-related increase in macrophage numbers from 30% with no acemannan to 45% with 0.2 μg of acemannan per well. Since data are expressed as percent cells, there was a concomitant reduction in lymphocytes. At 96 hours there was also a dose-related increase in the percentage of macrophages in the presence of acemannan. At 96 hours, the cultures with 0.2 μg of acemannan per well showed significant acidosis, as indicated by a yellow coloring. Furthermore, 96-hour cultures had a lower percentage of macrophages, possibly due to the longer time in culture. To relate the acemannan-induced increase in macrophage numbers to a known standard, a similar experiment was conducted with the mitogen PHA-P. Results are shown in Table 4.

Table 4

**PERCENT CELL TYPES BY HISTOLOGICAL
EVALUATION OF MOUSE SPLEEN CELLS IN CULTURE**

	Time in Culture	Cells(a)	PHA-P ($\mu\text{g}/\text{well}$)			
			0.0	0.02	0.01	0.2
10	72 hours	macrophages	33 \pm 8	32 \pm 6	30 \pm 6	31 \pm 5
		lymphocytes	70 \pm 12	68 \pm 8	70 \pm 6	69 \pm 4
	96 hours	macrophages	18 \pm 6	21 \pm 3	26 \pm 6	25 \pm 5
		lymphocytes	77 \pm 10	79 \pm 4	74 \pm 8	75 \pm 6

15

(a) Monocytes were determined by esterase staining. The results are expressed as mean \pm S.D. The results are from six experiments. "Lymphocytes" are cells that did not stain by esterase and had the appearance of lymphocytes by Wright's stain.

20

Although the percentage of macrophages did not change at 72 hours, there was a dose-related increase in macrophages after incubation with PHA-P for 96 hours. By comparison, acemannan was twice as effective as PHA-P. The percentage of macrophages increased a maximum of 16 with acemannan compared to 7 with PHA-P (Tables 3 and 4).

25

Since acemannan appeared to increase the percentage of macrophages, it was decided to determine whether the activity of the phagocytes was also increased. Peritoneal exudate cells from CBA mice given saline, thioglycolate broth or acemannan were used [as phagocytes] with sheep red blood cells as the particles to be ingested (Table 5).

30

35

Table 5

**NONSPECIFIC PHAGOCYTOSIS OF SHEEP
ERYTHROCYTES BY PERITONEAL EXUDATE(a)**

5	Percent of Phagocytosis(b) Time (minutes)						
10	Trmt.	0	5	10	20	60	120
	Saline	3±3	11±6	15±10	25±9	45±12	52±15
	Thio.	1±1	14±8	20±8	52±14(c)	84±32(c)	89±21(c)
	Ace.	3±2	10±6	12±8	41±18	61±18	63±23

15

(a) The results were determined by counting 200 cells/slide with two slides/animal. The results are based on two experiments.

20

(b) Percent phagocytosis indicates the proportion of cells showing erythrocyte ingestion. The results are expressed as mean ±S.D.

25

(c) Significantly different from saline control group, assessed by the Student's t-test at the 95% confidence level.

30

Over a 120-minute period, nonspecific phagocytosis increased from 3% to 52% in saline controls, whereas percent phagocytosis in cells from thioglycolate broth-treated animals rose to 89%. Phagocytosis in acemannan-treated animals rose to 63% at 120 minutes. Acemannan-stimulated phagocytosis was greater than that in controls after 20-120 minutes; however, the differences were not statistically significant.

35

To determine whether the acemannan effect on phagocytosis was antibody-dependent, a similar experiment was performed with anti-SRBC (Table 6).

Table 6

ANTIBODY MEDIATED PHAGOCYTOSIS(a)

5	Phagocyte <u>Antibody Titer (x 103)</u> (b)					
	Source	Pretreatment	0	2	4	8
	Peritoneum	Saline	15±8	43±10	39±9	19±11
		Thioglycolate	49±11	89±22	80±22	58±14
10		Acemannan	36±14	73±13(c)	62±8	40±13
	Spleen	Saline	11±4	38±9	32±11	20±4
		Thioglycolate	29±9	73±13	54±16	38±12
15		Acemannan	21±10	60±9(c)	51±17	26±11
	(a) Phagocytosis is expressed as the mean % of cells showing erythrocyte ingestion ±S.D.					
20	(b) The antibody titer by agglutination was shown to be 1:1024. Pre-treatment and cell sources are discussed in Methods.					
25	(c) Significantly different from saline control, assessed by the Student's t-test at the 95% confidence level.					
30	Sera were inactivated with heat (56°C for 30 minutes), and the antibody titer used was 2×10^3 , well above the hemagglutination titer. In this experiment, macrophages were obtained from two sources, the peritoneal cavity and the spleen. Again, mice were pretreated with IP injections of 1 ml of 0.9% saline, 1 mg/kg thioglycolate or 1 mg/kg acemannan. At a titer of 2×10^3 , the phagocytic activity of thioglycolate-induced peritoneal macrophages was twice as great (89% vs. 43%) as activity from the saline-induced controls, whereas acemannan-induced macrophages were more active by 30% (73% vs. 43%) compared to controls. The difference between phagocytic activity in the acemannan-treated and saline control groups was statistically significant.					
35						

5 Similar results were seen with macrophages obtained from mouse spleens. Phagocytic activity was lower than that of macrophages obtained from the peritoneal cavity, possibly due to manipulations of the spleen cells. Again, at a titer of 2×10^3 , acemannan-induced macrophages were significantly higher in phagocytic activity than saline controls at the 95% confidence level; phagocytic activity was similar to control at a titer of 8×10^3 .

10 To determine the effect of complement (C') on antibody-mediated phagocytosis, an experiment utilizing addition of C' to media was undertaken. (Table 7).

Table 7

**COMPARISON OF COMPLEMENT-MEDIATED
PHAGOCYTOSIS**

5	Cell Source	Phagocyte Inducer	<u>% Phagocytosis(a)</u>	
			+C'	-C'
10	Peritoneum	Saline	24±11	18±9
		Thioglycolate	84±10	62±12
		Acemannan	70±8(b)	54±4
15	Spleen	Saline	18±11	16±9
		Thioglycolate	54±9	41±11
		Acemannan	48±10	35±6

(a) Phagocytosis is measured as percent uptake of sheep erythrocytes ±S.D. after incubation for 30 minutes. Guinea pig complement was added.

(b) Significantly different compared to -C', assessed by the Student's t-test at the 95% confidence level.

To assure that lysis would not occur, IgM-depleted mouse serum was used (see Methods). The titer utilized was 3000, as determined by hemagglutination and the Coombs technique. Cells from both the peritoneal cavity and spleen were more active in phagocytosis with the addition of C' than without C', although the difference was statistically significant only with peritoneal cells induced by acemannan.

Finally, an experiment was performed to differentiate the effect of acemannan phagocytosis and adherence (Table 8).

Table 8

COMPARISON OF PHAGOCYTOSIS AND ADHERENCE(a)

5	Cell			
	Source(b)	Pre-treatment	Phagocytosis	Adherence
10	Peritoneum	Saline	5±8	6±4
		Thioglycolate	12±9	23±9(c)
		Acemannan	11±9	18±10(c)
15	Spleen	Saline	8±7	14±11
		Thioglycolate	14±6	36±10(c)
		Acemannan	10±8	20±7(c)

(a) Cell mixtures were allowed to incubate for 7 minutes.

20 (b) Results are reported as percent phagocytes showing phagocytosis or adherence ± S.D. The results are from one experiment with 200 cells scored/animal with three animals used.

25 (c) Significantly different from saline controls, assessed by the Student's t-test at the 95% confidence level.

30 In this experiment, antibody to SRBC was used in a titer of 2,000, but the experiment was stopped after 7 minutes. Acemannan-induced macrophages from both the peritoneum and spleen were more efficient in adherence than the saline controls and, as seen previously, less efficient than the thioglycolate-induced group.

C. Discussion

The results indicate that acemannan both directly and indirectly stimulates phagocytosis. The results also indicate that acemannan enhances phagocytosis by macrophages, both non-specifically and specifically, through antibody-mediated reactions. This demonstrates that acemannan has immunostimulatory properties on phagocytes.

Example 3

THE EFFECTS OF ACEMANNAN ON NONSPECIFIC TUMOR LYSIS

This example investigates the possibility of nonspecific tumor death induced by acemannan-stimulated phagocytes.

A. Procedures

Acemannan Polymer: Acemannan was kept in a dried form. The amount needed for each experiment was weighed and microwaved in 2-minute exposures at 600 watts of power. The material was transferred to a sterile centrifuge tube (15 ml) and microwaved for one additional minute. The material was diluted in Hanks Balanced Salt Solution (HBSS) to the concentration needed. In some experiments, material was sterilized by autoclaving, with no apparent loss in activity.

Cells: Macrophages were harvested from the peritoneal cavity of BALB/c female mice obtained from Harlan/Sprague Dawley. Either thioglycolate broth (25 mg/kg) or acemannan (25 mg/kg) was injected IP into some groups of animals 6 days before harvesting. Saline stimulated cells were also utilized as an additional control. Harvested cells were washed three times in HBSS and diluted in RPMI-1640 to a concentration of 5×10^6 /cells/ml.

Target cells: Target cells were obtained from the American Type Culture Collection (C3H/HeN Fibrosarcoma L929) and maintained in passage. Labeling was done with 150 mCi of ^{51}Cr mixed with 1 ml of the cell suspension containing 10^7 cells in RPMI-1640. Cells were incubated for 1 hour, washed with RPMI-1640 three times and adjusted to a final concentration of 5×10^4 cells/ml.

B. Assay

Aliquots of effector cells (100 cells/ μ l) were placed in flat-bottomed microtiter plates. ^{51}Cr -labeled cells were added with a minimum of three replicates per experimental point. Test plates were incubated at 37°C in 7% CO_2 (previously 5% CO_2) for 20 hours. Supernatants (100 μ l), were obtained after centrifugation of the plates at 250 x G for 15 minutes. The amount of radioactivity was assayed on a Packard gamma counter. Controls consisted of thymocytes. The percent of cytotoxicity (%CT) was determined by:

$$\%CT = \frac{\text{cpm in test cells} - \text{cpm in control cells CT}}{\text{total cpm of target cells}}$$

C. Results

Table 9 shows the results of the initial experiments.

Table 9**EFFECT OF ACEMANNAN ON CYTOTOXICITY**

	Cells	cpm \pm S.D.(a)	percent cytotoxicity
25	thioglycolate stimulated <u>in vivo</u>	2,800 \pm 300	6.6
	thioglycolate stimulated <u>in vitro</u>	2,950 \pm 260	7.0
	nonstimulated	2,870 \pm 400	6.8
30	Acemannan-stimulated <u>in vivo</u>	3,100 \pm 360	7.4
	Acemannan-stimulated <u>in vitro</u>	21,000 \pm 900	50.0
35	Acemannan-stimulated <u>in vivo</u> and <u>in vitro</u>	20,500 \pm 1100	48.8

(a) total cpm of target cell = 42,000

Thioglycolate-stimulated macrophages incubated with ^{51}Cr target cells released ^{51}Cr at an average of 2800 cpm, whereas acemannan-labeled cells released radioactivity at an average of 3100 cpm. There was no statistical difference between these groups. Nonstimulated macrophages released in the range of 2800 cpm. However, macrophages stimulated with acemannan in vitro had a ^{51}Cr release of 21,000 cpm. This indicates two things: 1) acemannan does not induce a long standing cytolytic effect, and 2) its activation can occur in a relatively short time in tissue culture. The percent cytotoxicity is parallel to the cpm released from target cells when destroyed.

A subsequent experiment using the cytotoxic assay over time is shown in Table 10.

Table 10

TIME DEPENDENT EFFECT OF ACEMANNAN ON CYTOTOXICITY

Percent			
	Time(a)	Stimulation	cpm(b)
5	0	Acemannan	800
		Thioglycolate	780
10	3	Acemannan	1,400
		Thioglycolate	800
15	6	Acemannan	18,000
		Thioglycolate	1,200
20	9	Acemannan	22,600
		Thioglycolate	2,200
25	12	Acemannan	22,500
		Thioglycolate	2,300
30	15	Acemannan	23,000
		Thioglycolate	21,100

(a) Time in hours after injection

(b) Cpm control cells = 39,000

The cytotoxic effect of acemannan began within 6 hours after stimulation and increased to its maximum by 9 hours. The mechanism of this activation has not been investigated.

The data shown in this example indicate that acemannan may have an important role in the nonspecific therapy of cancer.

Screening of Acemannan for Potential Efficacy Against Equine Sarcoid. Three sarcoids on two horses were treated both parenterally and intralesionally with acemannan. The goals of

5 this trial were to determine whether acemannan might be an effective treatment against equine sarcoid and also to observe the horses for adverse reactions. On horse 1, one sarcoid completely resolved while a second sarcoid did not decrease in size. A third nodular sarcoid developed during treatment. On horse 2, a single sarcoid completely resolved. These results suggest that acemannan may be useful in the treatment of equine sarcoid.

10 Two horses with three suspicious lesions were purchased at a sale. The lesions were photographed, measured and confirmed by histopathology as sarcoids.

15 Horse 1: Day 1. Each of the two lesions on the right rear leg was treated by direct injection (20-ga. needle), with 50 mg acemannan diluted in 10 ml saline (lesion 1) and 5 ml saline (lesion 2). Twenty-five mg acemannan diluted in 7.5 ml saline was also given IV.

20 Day 7. Lesion 1 (upper lesion) was treated (18 ga. needle) with 50 mg acemannan diluted in 10 ml saline. Lesion 2 was treated with 25 mg diluted in 7.5 ml saline. Fifty mg in 10 ml saline was given IV.

Day 14. Lesion 1 was treated with 50 mg in 10 ml saline, whereas lesion 2 was treated with 25 mg in 5 ml saline. Seventy-five mg in 25 ml saline was given IV.

25 Day 21. Lesion 1 was treated with 50 mg in 10 ml saline, and lesion 2 was treated with 25 mg in 10 ml saline. One hundred mg in 25 ml saline was injected IV.

Day 29. Lesion 1 was treated as on day 21, but because of local swelling lesion 2 was not treated directly. One hundred mg in 25 ml saline was given IV.

30 Day 42. Lesion 1 was not treated directly. Lesion 2 was treated with 25 mg in 10 ml saline. One hundred mg in 50 ml saline was given IV.

35 Day 57. Horse 1 was euthanized. Tissue samples were taken at the site of lesion 1 and from lesion 2, inguinal lymph nodes and a nodular lesion on his left shoulder that had developed during the course of treatment.

Horse 2: Day 1. The lesion on the lower left thorax was treated with 50 mg acemannan diluted in 30 ml saline. One half was injected subcutaneously (S/Q) and the other half intralesionally.

5 On days 6, 16, 24, 30, 49, 56, 63, 70 and 77 horse 2 was given 100 mg acemannan IV diluted in 60-120 ml saline, the amount of diluent varying as required to make a clear solution.

10 On days 105, 113 and 120, the lesion was treated with 25 mg acemannan diluted in 5 ml saline, intralesionally and S/Q at the base of the lesion. An additional 75 mg was given IV.

Results-Horse 1: Day 1. Lesion 1 measured 2.5 cm (length horizontally) x 2.5 cm (height vertically) x 1 cm (thickness). The resolution of this lesion can be followed below:

15 Horse 1 - Lesion 1

Day Measurements

	1	2.5 cm x 2.5 cm x 1 cm
20	7	2.5 cm x 1.75 cm x 1 cm
	14	2.0 cm x 1 cm x 1 cm
	21	2.0 cm x 1 cm x now flush with skin level
	29	2.0 cm x 1 cm x flat and dry
	42	all but healed
25	54	completely healed

Lesion 2 measured 2 cm x 2 cm x 1 cm on Day 1 and never changed significantly.

50

Horse 1 - Lesion 2

	Day	Measurements
5	1	2 cm x 2 cm x 1 cm
	7	2 cm x 2 cm x 1 cm
	14	2 cm x 2 cm x 1 cm
	21	2 cm x 2 cm x 1 cm
	29	2 cm x 2 cm x 1 cm - entire hock still swollen
10		and painful
	42	size slightly less - still swollen, not as painful
	54	same size - hock swelling down 65%
15		

Results-Horse 2: Day 1. The lesion measured 5 cm x 3.5 cm x 2.5 cm with a pedunculated base of 2.5 cm. The changes until complete resolution are shown below:

20 Horse 2 - Lesion 1

	Day	Measurements
25	1	5 cm x 3.5 cm x 2.5 cm
	6	no change
	16	no change - more granulomatous
	24	5 cm x 3 cm x 2.5 cm
	30	less granulomatous
30	49	4 cm x 3 cm x 2 cm
	56	4 cm x 3 cm x 2 cm
	63	3.8 cm x 3 cm x 2 cm
	70	3.7 cm x 2.6 cm x 1.8 cm
	77	2.7 cm x 2 cm x 1.3 cm
35	105	2.5 cm x 2 cm x 1.3 cm
	113	3.5 cm x 2.25 cm x 1.5 cm
	120	2.5 cm x 2.4 cm x 0.6 cm
	177	Lesion completely resolved

After IV administration to these horses, there were no changes in heart rate, no sweating, muscle fasciculation or obvious signs of distress. A slight increase in depth of respiration was noted in horse 1 only. Locally, horse 1 showed an inflammatory cellulitis of a mild nature at lesion 1 and of an acute painful type at lesion 2, enough so that the lesion was not injected as scheduled on day 29. Lesion 2 was more fibrous and much more difficult to inject, so that there was more leakage S/Q. This could account for the lack of effect on lesion 2. Horse 2 did not show cellulitis.

The fact that a nodular sarcoid developed during the course of treatment leads one to suspect that the main effect of acemannan is a local tissue reaction rather than a systemic one, although IV administration may sensitize the sarcoid to intralesional treatment.

The exact date at which the lesion on horse 2 resolved is unknown because the investigator was on a 60-day sick leave between day 113 and day 177. Judging from the lack of significant reduction in tumor size by day 56, it would appear that weekly IV administration alone had little effect on the sarcoid on horse 2.

Example 4

ENHANCEMENT OF ALLO-RESPONSIVENESS OF HUMAN LYMPHOCYTES BY ACEMANNAN

This example was designed to test the capacity of acemannan to enhance immune response to alloantigen and to test whether the potential enhancement is a monocyte-driven phenomenon. Acemannan did not enhance lymphocyte response to syngeneic antigens in the mixed lymphocyte culture (MLC), but, importantly, it increased alloantigenic response in a dose-response fashion (2.6×10^{-7} - 2.6×10^{-9} M). This effect of acemannan was shown to be a specific response and to concur with concentrations of in vitro acemannan achievable in vivo. A separate series of mixing experiments demonstrated that acemannan incubation with monocytes permitted monocyte-driven signals to enhance T cell response to lectin. It is

concluded that acemannan is the active ingredient of the Aloe vera plant and is an important immunoenhancer in that it increased lymphocyte response to alloantigen. It is suggested that the mechanism involves enhancement of monocyte release of IL-1 under the aegis of alloantigen. This mechanism may explain in part the capacity of acemannan to abrogate viral infections in experimental animals and man.

This example was designed to directly assess the impact of acemannan as an immune enhancer in the model of monocyte-T-lymphocyte, cell-cell interaction response to alloantigen presented in the mixed lymphocyte culture. This model tests the capacity of acemannan to stimulate additional monocyte-macrophage functions in an immunologically relevant model.

A. Materials and Methods

1. Cell Preparation. Mononuclear leukocytes were obtained from the peripheral blood of normal, informed and consenting human volunteers under the aegis of a study approved by the Institutional Review Board of the University of Texas Southwestern Medical Center at Dallas. Peripheral blood was diluted 1:3 in Hanks' balanced salt solution (HBSS) and layered on top of a ficoll-hypaque gradient. Cells from subjects known to be major histocompatibility disparate were obtained on each study day to ensure a positive mixed lymphocyte reaction. For specific experiments, more carefully characterized pedigrees of cells which inhibit the mononuclear leukocyte pool were isolated. T-lymphocytes were isolated by the standard nylon wool separation technique. The nylon effluent cells contained about 90% pure T cells. T-8 lymphocytes and monocyte-macrophages preferentially adhere to the column. The adherent population was removed by forcibly pushing media through the column with a plunger. To enrich for monocytes (macrophages), the glass adherence procedure was utilized to produce a population greater than 95% pure.

2. Acemannan. Acemannan was tested in these studies by preparing a 0.5% (w/v) solution in RPMI-1640

medium and further diluting to the following working concentrations:

$2.6 \times 10^{-7}\text{M}$, $2.6 \times 10^{-8}\text{M}$ and $2.6 \times 10^{-9}\text{M}$.

3. Mixed Lymphocyte Cultures (MLC). Unidirectional MLC were set up in microtiter, flat-bottom tissue culture plates (Costar Co., Cambridge, MA). Mononuclear cells, isolated by the ficoll-hypaque density gradient technique discussed above, served as stimulator cells after exposure to 2000 rads for 30 minutes in a cesium source (Gammacell, Atomic Energy of Canada, Ontario, Canada). Responder cells that had been similarly isolated and stimulators were adjusted to 1.3×10^6 cells/ml. To each well the following were added: 25 μl of acemannan or media (control), 25 μl of RPMI-1640 supplemented with 10% fetal bovine serum and 75 μl of each cell population. Cells were incubated at 37°C in 5% CO_2 : 95% air for 6 days. Cultures were pulsed with 25 μl of ^3H -thymidine (1 $\mu\text{Ci/well}$) for 4 hours, after which the cells were harvested and counted. To test the specificity of acemannan on the afferent recognition and response to MLC, additional unidirectional MLC were set up with the agent added just 20 minutes before the cells were pulsed with ^3H -thymidine.

4. Monocyte-T Cell Interaction. Lewis female rat spleens were teased through a sterile steel mesh into RPMI-1640 medium. Mononuclear leukocytes were collected from the interface of a ficoll-hypaque density gradient as described above. Monocytes, obtained by enrichment on glass petri dishes and adjusted to a final concentration of $10^6/\text{ml}$, were incubated with varying doses of acemannan or medium (control) in a total volume of 2 ml and incubated for 24 hours at 37°C . The monocytes were harvested, extensively washed with fresh medium and co-cultured with syngeneic T lymphocytes at a ratio of 10 T-cells:1 monocyte, with the plant lectin phytohemagglutinin (Difco, Detroit, MI) (1:100) for 48 hours at 37°C . Cells were harvested over a MASH II (Whittaker, MA Bioproducts, Walkersville, MD), placed in fluor and counted in a scintillation counter (Beckman Laboratories, Chicago, IL). A control experiment was performed by incubating T lymphocytes

with acemannan, followed by wash and co-culture with freshly prepared T lymphocytes, again at 10:1 along with PHA-P.

B. Results

5 1. Alloantigenic Response. Acemannan had no statistically important effects on the response of T-cells to autoantigens. When the agent was added at the beginning of MLC, cells receiving syngeneic stimulation incorporated tritiated thymidine equally in the presence or absence of test reagent at the doses described. In the absence of oral acemannan these
10 MLC incorporated 2616 ± 1099 cpm of tritiated thymidine at the end of a 4 hour pulse. Although there was a trend upward with respect to the dose of agent added (3281 ± 1355 at $2.6 \times 10^{-9}M$, 3742 ± 1670 at $2.6 \times 10^{-8}M$, and 3828 ± 1978 at $2.6 \times 10^{-7}M$), none of these rates of isotopic incorporation into DNA was
15 different to a statistically significant degree.

 In contrast to the absence of effect of acemannan on autoresponse in the MLC was the agent's effect on alloresponse in the same immunologic assay. First, acemannan did not interfere with the capacity of lymphocytes to recognize and
20 respond to class II alloantigenic differences in the MLC; this was apparent when the syngeneic cultures were compared to the allogeneic response in the presence of the lowest concentration of drug. Second, there was a dose-response-related enhancement of alloresponse by acemannan such that the
25 culture treated with the highest dose, $2.6 \times 10^{-7}M$, reflects a nearly 60% increase over the non-acemannan culture. The dose response relationship is most convincingly demonstrated as the enhanced allogeneic response is shown to be significant for each dose of acemannan tested with respect to the no acemannan
30 condition.

 To ascertain whether acemannan exerts a specific effect on lymphocyte alloresponse or a nonspecific effect on tritiated thymidine incorporation, the reagent was added at the conclusion of a 7 day mixed lymphocyte culture MLC, 20
35 minutes before addition of the tracer to the culture. There was no effect of acemannan when added in this manner as a pulse at the conclusion of the MLC. These data support the specificity of

the acemannan effect on enhancement of lymphoid response in the MLC.

5 2. Acemannan and Monocyte-T Cell Cooperation. To
test the hypothesis that acemannan directly stimulates the
monocyte responding to alloantigen to provide signal(s) to
enhance lymphoid response to antigen and/or mitogen, purified
populations of monocytes were incubated for 24 hours with
various doses of acemannan. At the conclusion of the
incubation the cells were washed extensively and then co-
cultured with T lymphocytes at a ratio of 10:1, to simulate the
natural ratio found in peripheral blood. Co-cultured cells were
stimulated with phytohemagglutinin. The co-cultures with
monocytes that were previously incubated with acemannan had
a significantly increased mitogenic response in a dose-related
fashion.

C. Discussion

This example has explored the capacity of acemannan to function as an immunostimulating drug with important clinical consequence.

20 Acemannan is believed to be capable of limiting DNA and
retrovirus infections that cause significant diseases in animals
and in man. For example, in an animal model, acemannan
ameloriated feline viral rhinotracheitis. Additional evidence
shows that acemannan in vitro and in vivo may be effective
25 against Herpes simplex II virus, the measles virus, and perhaps
HIV. Evidence indicates that the immunological mechanism
may involve enhancement of the monocyte, both as a
phagocytic cell and as a cell that contributes to afferent
recognition of antigen. Studies have shown direct enhancement
30 of phagocytic properties of the monocyte, on the one hand, and
an increase in the absolute numbers of that important cell, on
the other. Mounting evidence supports the concept that
acemannan enhances the elaboration by the activated monocyte
of the signal substance IL-1.

35 The studies described in this example were directed
specifically at exploring the mechanism by which acemannan
may be an immuno-enhancing reagent. Mixed lymphocyte

5 cultures are in vitro models of the manner in which immunocompetent cells participate in response to antigen of the variety that is necessary for recognition and response to virus. In this reaction, there are important monocyte-T-lymphocyte interactions that generate a response to alloantigen. It was this model that was chosen for testing the capacity of the acemannan to function as an immunoactivator.

10 Acemannan is therefore an important enhancer of the alloantigenic response in MLC. There is a dose-response relationship with enhancement at the highest dose tested of about 60% above basal. This represents not only a statistically significant but also a biologically relevant increase in response to alloantigen and may serve as one means by which the drug can aid the response of the organism to viral assault. This effect of acemannan was shown to be specific for the allogeneic stimulus, provided the drug did not enhance either basal response to self (syngeneic MLC) or non-specific incorporation of a tracer DNA precursor, tritiated thymidine, when drug was added at the conclusion of the MLC.

15 A second series of experiments tested the hypothesis that monocyte-T-lymphocyte interactions may be, at least in part, responsible for the heightened alloresponse in the MLC. In this series of experiments acemannan was incubated along with monocytes, after which the treated, extensively washed monocytes were mixed with freshly prepared, syngeneic T-lymphocytes that had not been exposed to and would not be exposed to acemannan. These experiments demonstrate the enhancement of T-lymphocyte response to the polyclonal mitogen phytohemagglutinin at a magnitude equal to the response that had been seen previously in the MLC--approximately 55% above baseline and dose-response relationship.

20 The lowest dose that was tested in the study that was effective in the MLC had no effect in the monocyte experiment. It is not surprising that the threshold dose may be different for the two models tested, polyclonal response to mitogen and alloantigenic response in the MLC. It can also be observed that

the monocyte experiment is a more stringent test of the effect of acemannan because it presents a treated cell type, the monocyte, to T cells that then see an immune stimulus in the absence of the drug. While the alloantigenic response may be due solely or in great measure to acemannan-enhanced monocyte production of IL-1, the lesser polyclonal mitogen-enhanced response may be a consequence of an assay of immune stimulations, each with a different threshold response to acemannan.

The dose of acemannan used in these experiments is clinically relevant. The dose range selected was chosen precisely to bracket that concentration of acemannan that could be expected to be achieved in plasma if the drug distributes in extracellular water and is absorbed at the rate of a third of the orally-administered dose, figures that were based on previous pharmacologic studies in dogs. The actual concentrations achievable in man have also been shown to be in this range, further supporting the potential relevance of these studies for clinical practice.

Acemannan was shown by these experiments to cause monocytes to release monocyte-driven signals to enhance T4 cell response to lectin. While acemannan did not enhance lymphocyte response to syngeneic antigens in MLC, it did increase MLC alloantigenic response in a dose-related manner. This response was shown to be an acemannan-specific response at acemannan concentrations achievable in vivo.

This experimental documentation demonstrates that acemannan is an immunoenhancer and biological response modifier in that it increases lymphocyte response to alloantigen. A proposed mechanism of action involves stimulation of monocytes to release IL-1; in the presence of acemannan, IL-1 has been shown to be released from monocyte cultures. The pharmacologic action of acemannan stimulation of monocytes may explain acemannan activity against viral infection in animals and man.

Example 5
PHARMACOKINETIC BASIS FOR CORRELATION OF
IN VITRO AND IN VIVO EFFECTIVENESS
OF ACEMANNAN

5 To evaluate the pharmacokinetic behavior of acemannan, ^{14}C -labelled material was given by IP and IV injection and PO administration. Based on the results of previous pilot work, an aqueous dose of 200 mg ^{14}C -labelled acemannan/200 ml with specific activity of 17.4 cpm/ μg was administered to female
10 dogs (approximately 20 mg/kg). Blood, urine and feces samples were taken at appropriate intervals for 48 hours or longer. Organ and tissue samples were taken after sacrifice, and all samples were analyzed for radioactivity using scintillation spectrometry.

15 Acemannan's kinetic behavior was typical of that seen with most pharmacologic agents; however, its biologic half-life ($t_{1/2}$) was extraordinarily long. Significant absorption occurred by all three routes of administration. Maximum blood levels were achieved after IV injection followed by IP and then PO.
20 Blood levels, which were immediately maximal at 200 $\mu\text{g}/\text{ml}$ after IV injection, declined with a $t_{1/2}$ of 50-60 hours; plasma levels were approximately twice those of blood. By comparison, after IP injection blood levels peaked at 45 $\mu\text{g}/\text{ml}$ at 24 hours and then declined at a rate similar to that seen with IV; in fact,
25 blood levels were nearly 90% maximal after only 8 hours. With oral administration, blood levels were measurable after 3 hours and peaked at 4-5 $\mu\text{g}/\text{ml}$. Based on the relatively long half-life in blood, a therapeutic dosing interval of approximately 7 days would be justified, considering the time required for three half-
30 lives.

 Radiolabeled acemannan distributed mainly in liver and spleen following IP or IV injection. Liver, marrow, thymus, and lymph nodes were primary sites of distribution after oral dosing, a finding consistent with the immunologic sites of action
35 for acemannan. Levels of radiolabeled compound in tissues sampled after 48-52 hours ranged from a low of approximately 1 $\mu\text{g}/\text{g}$ brain to a high of 85 $\mu\text{g}/\text{g}$ spleen after IV injection.

Interestingly, levels in brain and spinal cord were higher (approximately 3 $\mu\text{g/g}$ tissue) after oral, compared to parenteral, administration. This could be the result of the liver's partial breakdown of the polymer into smaller molecular weight fractions during the first pass, thus rendering it capable of penetrating the blood-brain barrier.

In summary, with respect to clinical pharmacokinetic considerations, the data indicate that ^{14}C -labelled acemannan (1) reaches peak blood levels within 8 hours or less by all routes studied, (2) has a relatively long biologic half-life, which would allow therapeutic dosing intervals of several days, and (3) achieves measurable levels in all tissue systems evaluated, including the central nervous system.

These pharmacokinetic data indicate that acemannan levels in blood and/or tissue can duplicate those levels known after injection or oral administration to produce therapeutic antitumor or antiviral effects in vitro. For example mice implanted with virally-infected Norman Murine Myxosarcoma (NMM) cells and injected IP within 24 hours with 1 mg/kg of acemannan showed 35% survival after 60 days compared to 0% survival in NMM-treated control mice (Peng et al., submitted for publication, 1990). Expected peak blood levels at an IP dose of 1 mg/kg would be on the order of 2 $\mu\text{g/ml}$ ($45 \mu\text{g/ml} \times 1/20 \text{ mg/kg}$). Acemannan added to cultures of T-lymphocytes at a concentration of only 0.15 $\mu\text{g/ml}$ ($2.6 \times 10^{-9} \text{ M}$; 60,000 MW) increased the generation of cytotoxic T-cells 230% and increased the functional capacity of generated cytotoxic T-cells by 138% to destroy target cells against which they had been sensitized [Womble et al., Int. J. Immunopharmac. 10(8):967-974 (1988)]. Cytotoxic T-cells are thought to be generated against tumor cells like NMM cells.

Blood levels of 4-5 $\mu\text{g/ml}$ obtained after oral administration of acemannan are also significant, since they correspond to the concentration of acemannan that gives optimal synergism with Zidovudine® (AZT) in vitro. For example, alone 0.001 $\mu\text{g/ml}$ AZT or 3.2 $\mu\text{g/ml}$ acemannan

increased the viability of CEM cells infected with HTLV-III_{RFII} virus by no more than 10%. Together the protective effect of the antiviral combination exceeded 70%. Similarly, a combination of 0.1 µg/ml of AZT and 1 mg/ml acemannan resulted in a protective effect exceeding 80% (Kemp et al. submitted for publication 1990).

Thus, in conclusion, this pharmacokinetic study demonstrates that acemannan concentrations at least as great as those known to work in vitro are attainable in vivo.

10

Example 6

REPORT OF TWO INITIAL CLINICAL PILOT STUDIES OF ACEMANNAN IN HIV-1-INFECTED PATIENTS

15

20

25

Before the discovery that infection with human immunodeficiency virus type 1 (HIV-1) posed a worldwide health threat, there had been only limited development of antiviral drugs. Despite the recognition that more than 60% of all illnesses in developing countries are caused by defined viral diseases, very little progress had been achieved in this area. Treatment for the most part consisted of the application of palliative measures designed to provide comfort and relief of symptoms rather than to interfere with the replication of viruses. The pandemic of AIDS, because of the total ineffectiveness of palliative or symptomatic treatment, has resulted in the initiation of unprecedented research into new antiviral compounds targeted to interfere with the replication cycle of HIV.

30

35

In the case of the human immunodeficiency viruses, most attention has been directed towards synthesis and development of 2',3'-dideoxynucleoside analogs, a class of antivirals that inhibit the virus-encoded reverse transcriptase. One of these compounds, AZT, remains the only drug approved for the treatment of AIDS. Unfortunately, numerous studies have demonstrated that the compound is extremely toxic in vivo, and its efficacy, although high in vitro, may be considerably less so in vivo [Richman et al., *N. Engl. J. Med.*, 317:192-197 (1987)].

Two studies assessed the response of human immunodeficiency virus type 1 (HIV-1) infection to acemannan

and determined whether laboratory values could be used to predict response to treatment. The protocol was submitted to the FDA, as an individual physician investigational new drug exemption and approved by the Institutional Review Board of the Dallas-Ft. Worth Medical Center. Subjects who were HIV-1 antibody positive and symptomatic were treated with approximately 400-800 mg oral acemannan daily and evaluated clinically using modified Walter Reed (MWR) clinical scoring. CD4/CD8 lymphocyte counts and HIV-1 (p24) core antigen levels indicated immune competence and active virus load. In the first study, the 15 original subjects had an average MWR of 5.6, but after 350 days of therapy the surviving 13 had an average of 1.8. CD4 levels in ten subjects increased from 346/mm³ to 471/mm³ within 90 days and to 610/mm³ at 180 days. Five of the 15 patients had detectable serum core antigen; by 350 days only 3 of 13 had detectable, but reduced, serum antigen. Data from this first study suggested that values for CD4 and serum antigen levels could predict the response to acemannan. A second study with 26 subjects confirmed this. The aggregate group had an average MWR of 3.0 at the start, and 90 days later their average was 1.8. The CD4 levels of 16 "responders" rose from 313/mm³ to 372/mm³ during this period, but in 10 others went from 63/mm³ to only 77/mm³. Fifteen of 16 individuals predicted to respond favorably had improved MWR, increased CD4 counts and reduced antigen, indicating that the extent of immunosuppression and viral load influences response to therapy.

Example 7

A PHASE II STUDY OF ACEMANNAN ALONE AND WITH AZT AMONG SYMPTOMATIC AND ASYMPTOMATIC HIV PATIENTS

Forty-seven HIV+ patients (23 asymptomatic patients, 24 ARC patients) participated in a double-blind randomized phase II study of acemannan. The protocol was approved by the relevant ethical committees of the Hospital St. Pierre in Brussels, Belgium. In order to evaluate safety and tolerance, with or without concomitant AZT therapy, acemannan was

administered during 24 weeks at a daily dose of 1000 mg (2 capsules of 125 mg, 4 times daily). The 23 asymptomatic patients were blindly allocated to receive either acemannan (11 patients, group 1) or placebo (12 patients, group 2). Of the 24 ARC patients who received 1000 mg AZT daily during the study, 12 patients (group 3) also received acemannan 1000 mg (2 capsules of 125 mg, 4 times daily) and 12 patients (group 4) also received placebo. Thirty-three out of 47 patients (70%) completed the 24-week study period (respectively 6, 9, 9 and 9 in the 4 groups). Reasons for withdrawals were: clinical evolution (8 patients: 3, 3, 0, 2), patients' own will (5 patients: 2, 0, 2, 1), or death (1 patient committed suicide in group 3). None of the patients dropped from the protocol because of side effects or poor tolerance. There was a statistically significant difference in the incidence of adverse drug reactions, mainly nausea, between groups 1&2 and 3&4, due to AZT therapy. No difference occurred between acemannan groups (1&3) and placebo groups (2&4). Hematological data were statistically comparable among 4 groups at study entry. At week 24 there were statistically significant differences for red blood cell count and mean corpuscular volume between patients with or without AZT but no difference between placebo and acemannan patients. There was no liver or renal toxicity among the 4 groups.

The 12 patients treated with AZT and acemannan (group 3) showed a statistically significant improvement of Karnofsky score (K) after therapy ($p < 0.008$) (mean K=84 at entry, 90 at exit) when compared to patients treated with AZT alone (group 4) (mean K=81 at entry, 83 at exit). There was no statistically significant difference between group 3 and 4 regarding occurrence of adverse events although 2 patients treated with AZT alone developed AIDS (1 Kaposi, 1 esophageal candidiasis) compared to none under combination therapy. Comparison of CD4 cell count of AZT-treated patients showed a significantly greater improvement ($p = 0.01$) at the end of the study among those treated with combination therapy (mean CD4 263/mm³ at entry, 369/mm³ at exit in group 3 compared to 145/mm³ at

entry and 252/mm³ at exit in group 4). We conclude that acemannan is a very well-tolerated compound with no biological toxicity and that among ARC patients acemannan would have a role as adjunctive therapy to AZT in the management of HIV infection.

Example 8

CONCENTRATION-DEPENDENT INHIBITION OF HIV-1 REPLICATION AND PATHOGENESIS BY ACEMANNAN IN VITRO

Peripheral blood mononuclear (PBM) cells and two defined CD4⁺ cell lines, MT-2 and CEM-SS, were used as target cells for HIV-1 infections and treated with various concentrations of acemannan. Viabilities were determined either by the trypan blue dye-exclusion test or by metabolic conversion of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide] to formazan by viable cells. Virus replication and load were measured by hybridization of cell-associated viral RNA and cell-free RNA with an HIV-1 probe prepared from the *POL* gene. Protection of PBM cells by acemannan treatment was shown to be concentration-dependent. Percent protection ranged from 14-100% for cells treated with 3.2-100 µg/ml of acemannan. Protection by acemannan treatment of HIV-1-infected MT-2 cells was not only concentration-dependent but also multiplicity of infection-(MOI) dependent. Protection of CEM-SS cells infected at an MOI=0.01 and treated with 62.5 µg/ml of acemannan exceeded 85%. In addition to an increase in cell viability, a concentration-dependent reduction in syncytium formation was observed. Syncytia could not be detected in cultures treated with ≥62.5 µg/ml of acemannan. A concentration-dependent reduction in virus replication was also observed for treated PBM cells. Treatment of PBM cells with concentrations of acemannan ≥62.5 µg/ml resulted in a 95-100% reduction in detectable cell-associated viral RNA. Treatment of virus-infected CEM-SS cells with acemannan concentrations ≥62.5 µg/ml caused >60% reduction in cell-free virus. Acemannan treatment inhibits virus-induced cell fusion, increases infected cell viability,

reduces virus load and suppresses production and/or release of free virus. Cytotoxicity due to acemannan was not observed at any test concentration.

Example 9

5 SYNERGISTIC ANTIVIRAL EFFECTS OF ACEMANNAN IN COMBINATION WITH AZT (ZIDOVUDINE)

The protective effects of combinations of AZT and acemannan were measured in vitro using HIV-1-infected MT-2 cells at a MOI of 0.03. Checkerboard titration of the two drugs indicated that a synergistic protective effect occurred. Concentrations of acemannan of less than 125 µg/ml were most effective in this respect.

10 It is now clearly recognized that some form of combination chemotherapy will be required in order to increase the efficacy of AZT while limiting its long term toxic effects and circumventing the further development of resistant HIV strains. For this reason, as well as the obvious beneficial effects of acemannan on clinical HIV infection when administered with AZT, it was decided to determine whether these two compounds had a synergistic inhibitory effect on HIV replication in vitro.

20 Virus Strains - The HTLV-IIIB strain of HIV-1 was obtained from Dr. R. Gallo, NIH, Bethesda, Maryland. Viral stocks were prepared by propagating the virus in H9 lymphoid cells. A stock preparation of the virus was stored at -80°C. The 50% tissue culture infective dose (TCID₅₀)/ml of cell-free virus pool stock was determined by end-point titration using MT-2 cells. Multiplicity of infection (MOI) was determined by the method of Reed and Muench.

25 Cell Lines - MT-2 cells were propagated in RPMI-1640 supplemented with 2 mM L-glutamine and 15% (v/v) fetal bovine serum. MT-2 cells naturally express CD4 on their surface and are thus good target cells for HIV-1 infection. In addition, they rapidly undergo cytolysis at low levels of virus replication.

30 Primary testing of antiviral activity - MT-2 cells were first treated with polybrene (2 mg/ml) for 30 min and then infected with HIV at a MOI of 0.03. After virus absorption, the

cells were pelleted and resuspended in complete medium. The infected cells were then dispensed (2×10^4 cells/100 μ l/well) into 96-well microtiter plates. Each drug was diluted in medium from a stock solution of 2 mg/ml in six serial half \log_{10} dilutions. AZT was tested from the highest concentration of 10 μ g/ml to a low concentration of 0.032 μ g/ml. Acemannan was tested at 500 μ g/ml and diluted down to a low concentration of 15.62 μ g/ml. Parallel assays were performed in triplicate, and drug cytotoxicity was measured at parallel concentrations in duplicate. Controls included uninfected, untreated cell cultures and virus-infected, untreated cultures. Plates were incubated for 7 days in a humidified atmosphere of 5% CO_2 in air. On day 7 post-infection, cell viability was measured by the addition of MTT (450 μ g/ml) to the test plates. A solution of 10% sodium dodecyl sulfate in 0.01N HCl was then added to dissolve the MTT formazan that was produced. The color intensity is a function of the amount of formazan produced which, in turn, is proportional to the number of viable cells in each well. Plates were read at a wavelength of 570 nm on a Vmax plate reader (Molecular Devices, Inc.). The percent change in cell viability was calculated using the following formula:

$$\% \text{ change in cell viability} = \frac{(\text{TI}-\text{TO})-(\text{OI}-\text{TO})}{(\text{OO}-\text{TO})-(\text{OI}-\text{TO})} \times 100$$

25

where:

TI is the optical density (OD) in treated, infected cells,
TO is the OD in treated, uninfected cells,
OI is the OD in untreated, infected cells, and
OO is the OD in untreated, uninfected cells.

30

Antiviral activity of acemannan-AZT combinations -
Antiviral activity of acemannan in combination with AZT at various concentrations was evaluated using the microtiter infection assay described above. For each mixture, defined amounts of the test compounds were dissolved in RPMI-1640,

35

and 0.1 ml of each dilution was added to test wells. Combinations were evaluated in duplicate, and treated uninfected controls were used to determine drug cytotoxicity. Each compound was also evaluated alone at non-cytotoxic concentrations. Thus AZT was tested at concentrations ranging from 0.32 to 10 $\mu\text{g/ml}$ and acemannan was evaluated at concentrations ranging from 15.62 to 500 $\mu\text{g/ml}$. The percent change in cell viability was determined as described above.

The effect of AZT-acemannan combinations on HIV-infected MT-2 cell viability is shown in Figures 1 and 2.

Acemannan alone conferred a maximum of 40% protection at a dose of 60 $\mu\text{g/ml}$. At higher doses the protective effect was erratic. AZT alone conferred a maximum of 60-67% protection at doses ranging from 0.03 to 0.32 $\mu\text{g/ml}$. Cytopathic effects could, however, be completely abolished by 0.32 $\mu\text{g/ml}$ AZT in the presence of 15.62 to 250 $\mu\text{g/ml}$ acemannan.

The data presented here clearly show that AZT and acemannan exercise a synergistic protective effect on MT-2 cells infected *in vitro* with HIV-1. These results support the clinical evidence for the same effect. Synergism, by definition, implies that the effect of the mixture of compounds is greater than the sum of their effects when acting alone. Thus when 0.01 $\mu\text{g/ml}$ of AZT was mixed with 15.62 $\mu\text{g/ml}$ acemannan (neither of which was protective on its own), 32% cell viability was achieved. Indeed, at unprotective acemannan concentrations of 31.25 and 15.62 $\mu\text{g/ml}$, significant enhancement in the protective effect of 0.1 $\mu\text{g/ml}$ AZT was seen.

When 0.32 $\mu\text{g/ml}$ AZT (65% protection) was mixed with 62.5 $\mu\text{g/ml}$ acemannan (40% protection), the mixture gave 100% protection. Obviously, in this case any synergistic effect would be hidden because it is not possible to detect a viability over 100% and the effect gives a spurious appearance of additivity.

The appearance of this synergistic effect implies that AZT and acemannan interfere with viral replication at different stages of its cycle. As a result, a sublethal hit at one stage in the HIV replication cycle may complement a hit at another stage. The combination of two hits collectively exerts a lethal effect on

the virus. AZT, of course, is well recognized as an inhibitor of the reverse transcriptase of the virus. Acemannan, on the other hand, possibly interferes with glycosylation and HIV envelope processing.

5

Example 10**ACEMANNAN USED IN TREATING CUTANEOUS ULCERS**

An 83-year-old female patient, TB, developed an ulcer, 25 mm in diameter, on the lateral margin of her left foot. The ulcer had been present for several months and had failed to respond to several treatment regimens.

10

The wound was treated with the product of Example 3 of U.S. Pat. 4,735,935 and the product of Example 7 of U.S. Pat. 4,735,935 using a three-times-daily treatment schedule. The clean wound was soaked for 15 minutes with the product of Example 2 of U.S. Pat. 4,735,935. Excessive product was absorbed from the wound with a dry, sterile 4 x 4 gauze. The product of Example 7 of U.S. Pat. 4,735,935 was then applied in a quantity sufficient to cover the wound and to prevent wound dehydration between dressing changes.

15

The progression of wound healing was measured by interval photographs and planimetry of the wound defect. The progression of wound closure is shown in Table 11.

20

TABLE 11
PROGRESSION OF WOUND HEALING

25

	Day	Wound Area (Sq. In.)	Percentage of Healing
	1	1.24	0.00
30	28	0.51	58.87
	77	0.29	76.61
35	83	0.12	90.32
	97	0.00	100.00

The epidermal defect was substantially closed in 12 weeks; complete closure occurred in 14 weeks.

Example 11

ACEMANNAN USED AS A TREATMENT FOR TIC DOULOUREUX

5

Tic douloureux, or neuralgia of the fifth cranial nerve, is characterized by attacks of severe, unbearable pain over one or more branches of the trigeminal nerve. The pain usually is transient, and attacks may be precipitated by touching some area of the face--the so-called trigger zone.

10

The cause and cure of this painful disease are unknown. Several attempts to treat the disorder have met with little or no success. Various treatments have included analgesics, phenytoin, peripheral avulsion of the involved nerve branch as it leaves the skull, and injection of 98% alcohol into the gasserian ganglion.

15

A more drastic treatment--sectioning the sensory root of the nerve proximal to the ganglion--leaves the patient permanently without sensation in the area supplied by the sectioned nerve. Another recent treatment attempt uses carbamazepine and phenoliophendylate injections. However, these injections can be complicated by unpleasant numbness and serious side effects.

20

None of the previously cited treatments is desirable.

25

A 43-year-old woman was diagnosed as having tic douloureux. The affected area included the first and third divisions of the trigeminal nerve on the right side.

30

The patient could trigger the pain by brushing or combing her hair on the right side. She had been treated unsuccessfully with diazepam (Valium), antihistamines, analgesics, propranolol hydrochloride (Inderal) and phenobarbital. The patient said she had not had a pain-free day since the onset of the disease.

35

The proposed therapy involved drinking 1 to 2 oz. of the product of Example 2 U.S. Pat. 4,735,935 daily for 3 months. After that period, the therapy was evaluated.

The patient's pain diminished significantly within 2 weeks of initiating therapy. She said she felt well for a few weeks.

However, she then went on a 2-week trip during which she did not drink the product, and symptoms and pain returned. After she resumed the medication, however, the pain disappeared within a few days. For the next few weeks, she again felt well.

5 After drinking the product daily for more than 6 months without interruption, she reports that she can brush and comb her hair without triggering the pain. Her appearance has improved, and she says she feels better than ever before.

Example 12

10 **AN EXPLORATORY CLINICAL PILOT STUDY UTILIZING ACEMANNAN IN INFLAMMATORY BOWEL DISEASE**

Inflammatory bowel disease (IBD) is a collective term for Crohn's disease, ulcerative colitis and other conditions of the gastrointestinal tract. Crohn's occurs mainly in the ileum and
15 colon, whereas ulcerative colitis is limited to the colon. At least three credible hypotheses have been set forth to explain the etiology of IBD. One holds that an unknown infectious agent, such as a slowly growing bacterium or virus, triggers the immune system and sets up a chronic inflammatory response.
20 The second holds that this same sequence of events is caused by a toxic substance, such as food-borne or environmental contaminants. The third hypothesis suggests that the inflammatory response is an autoimmune condition. However, the precise cause(s) of the disease remains unknown.

25 **A. Patient Selection.**

This study protocol was submitted to the FDA as an individual physician investigational new drug exemption and approved by the Institutional Review Board of the Dallas-Ft. Worth Medical Center. Patients were selected without regard to
30 age, sex, racial or ethnic background, and all patients were volunteers. Each received an informed consent briefing by the physician, and each was required to sign an informed consent form.

Only patients with a combination of the following
35 symptoms and signs of IBD were admitted:

1. Diarrhea (number of bowel movements)
2. Blood in stool (occult blood)

3. Excess mucus production
4. Spontaneous abdominal pain
5. Abdominal pain on palpation
6. Constant cramping
5 7. Other (weight loss, etc.)

The above symptoms were used to arrive at a clinical evaluation score of 0 to 7 with 1 indicating a single symptom and 7 indicating all symptoms were present. A score of 0 indicated the patient was asymptomatic.

10 **B. Endoscopic Evaluation.**

Endoscopy was utilized to score patients pre- and post-therapy according to the following criteria:

1. Ulcerations
-Confluent
15 -Spotty
-Linear
-Segmental
2. Hyperemia
3. Exudate
20 4. Other

The same experienced endoscopist scored listed mucosal appearances according to distribution and severity. A score of 0 indicated the patient had normal appearing mucosa, 5 denoted most severe.

25 **C. Histological Evaluations.**

Scoring of histological findings were recorded as follows:

- Exudate, Ulcerated mucosa, Edema, Plasma cells,
Lymphocytes,
Polymorphonuclear cells, Eosinophils, Granulomas, Crypt
30 abscess,
Fibrosis, Other

35 The above clinical, endoscopic and histopathological criteria were used to grade manifestations of IBD and to quantify response to acemannan treatment. Physical examinations with endoscopy and histological sampling were limited to regularly scheduled visits. Patients were permitted to withdraw at any time without cause and without impact

upon their usual therapy. Acemannan was furnished by Carrington Laboratories, Inc.

D. Clinical Results.

5 Nine IBD patients were admitted and were treated daily
with 200 mg acemannan in capsules. Patients ranged in age
from 14 to 46 years and included four females and five males.
Typically, the patients had abdominal pain, diarrhea or multiple
bowel movements; the stools were usually bloody and watery
with an increase in mucus production or a combination of these
10 elements. Initial endoscopic examination revealed a spectrum
of mucosal alterations ranging from vascular congestion with
mucosal friability to focal, extensive and confluent ulcerations,
termed "pan-colitis." Histological examination of bowel biopsies
revealed damage ranging from a non-specific increase in
15 chronic inflammatory cells to frank ulceration with numerous
polymorphonuclear cells and eosinophils. Two patients had
microgranulomata and crypt abscesses. All patients were
presented as nonresponsive to conventional agents, including
one or more of the following: Azulfidine, prednisone, 6-
20 mercaptopurine and Flagyl. Imodium and tranquilizers were
often added to the above agents.

The response to acemannan medication was uniformly
favorable, with all scores improving in all patients. The average
pre-and post-medication scores were as follows:

25	Average pre-treatment clinical score	4.56 (average of 9 patients)
30	Average post-treatment clinical score	0.44 (average of 9 patients)
	Average pre-treatment endoscopic score	3.88 (average of 8 patients)
35	Average post-treatment endoscopic score	0.00 (average of 2 patients)

Average pre-treatment histological score 6.25
(average of 8 patients)

Average post-treatment histological score N/A
(Pts all refused biopsy)

5

10 No adverse effects attributable to acemannan were observed at any time during the study. Some patients who were quite experienced with their own disease expression reported they were virtually free of pain and symptoms within 2-5 days. In others, particularly those with focal segmental disease (Crohn's and ileitis), the effects of acemannan were slower and less dramatic. All patients refused the post-treatment biopsy, and only two patients accepted post-treatment endoscopy. The following reasons were given by the patients: (1) these procedures are uncomfortable, and (2) the cost was not justified because of their improved condition.

15

20 Two patients were episodic in their intake of acemannan, taking it only when symptomatic. Both reported relief of symptoms in 24 to 48 hours after consuming the medication; however, mild symptoms returned in 4-6 weeks after discontinuance of acemannan treatment. Subsequently, 2-3 days of acemannan treatment again relieved symptoms. Acemannan provided dramatic clinical improvement in the acute inflammatory phase of the disease.

25

Example 13

THE IN VITRO EFFECTS OF ACEMANNAN ON MEASLES VIRUS

30

Measles virus was incubated with various concentrations of acemannan and then added to susceptible cultures of VERO cells. The purpose of this experiment was to determine whether acemannan would inhibit infection or inactivate measles virus treated with acemannan prior to introduction into a susceptible cell culture. Acemannan-treated virus did not infect the VERO monolayer as evidenced by the absence of cytopathic effects (CPE) of the virus at a threshold concentration

35

of 2.5 mg/ml. Complete absence of CPE was achieved at 5 mg/ml of acemannan in the virus inoculum.

5 African Green Monkey kidney cells (VERO cells) were used as the target cells. Measles virus was titrated to obtain a plaque count of 30-50 plaques/ml (20 TCID units/0.05 ml) on the virus/cell monolayer. Acemannan at different concentrations was then introduced into media containing this fixed amount of virus.

10 The concentrations of acemannan were made in complete tissue culture medium. An aliquot of rubella attenuated virus vaccine was used for each titration. The mixtures were pre-incubated at 30°C for one-half hour and added to previously prepared VERO monolayer in tissue culture chambers.

15 The results of combining measles virus with various concentrations of acemannan incubated five full days on confluent VERO cell monolayers are provided in Table 12.

20 Repetitious challenges with various concentrations of acemannan showed that a protective concentration was achieved between 2 mg/ml and 4 mg/ml, this being a transition zone for inhibiting measles virus infectivity. Note Table 12. It is apparent that the 5 mg/ml acemannan level consistently provided protection to the VERO cell monolayer challenged with measles virus pretreated with acemannan.

25 In this pilot study the effect of acemannan on measles virus was evaluated by comparing 1) VERO cells only (negative controls, 2) VERO cells inoculated with measles virus (positive controls), and 3) VERO cells inoculated with measles virus that had been pre-treated with acemannan. A significant reduction in plaque formation occurred in the acemannan-pretreated virus-infected cultures (#3) as determined by plaque count
30 assay. Complete protection of cultures from virus infection was achieved when virus was pretreated with 5 mg/ml acemannan.

Table 12

EFFECT OF ACEMANNAN CONCENTRATION

DATE	DIL	VIRUS DOSE	#	1	2	3	4	AV.	INF.
09/10/86	5	25	34	1(?)				1	0
		2.5		12.530				0	0 0
		1.25		6.2516				1	1 6.25
		0.625		3.12512				4	4 33.3
09/17/86	5	20	100+	0	0			0	0
		2.5		20	30			25	25
		1.25		60	30			50	50
		0.625		100+	100-			100+	100
		0.3125		100+	100+			100+	100
		0.1525		100+	100+			100+	100
10/08/86	5.0	20	100+	0	1			1	1
				1	0			1	1
				0	2			2	
				10	1			5.5	6
				9	0			4.5	5
				5	9			7	7
				0				0	0
	2.3	10		0				0	0
	1.0	5		0				0	0
								I	
10/12/86	5.0	20	5.5	0	0	0	0	0	0
				0	0	0	0	0	0
				0	0	0	0	0	0
				1	0	0	0	0.25	4.5
				1	0	0	0	0.25	4.5
				0	1	1	1	0.75	11
				0	0	0	0	0	0
	2.5	12.5		0	0	0	0	0	0
	1.0	6.25		0	0	0	0	0	0
10/01/86	5.0	20	6.0	0	0			0	0
				0	0			0	0
				0	0			0	0
				0	2			1	16.6
				1	2			1.5	25
				3	3			3	50
				0	0			0	0
	2.5	10		0	0			0	0
	1.0	5		0	0			0	0

Example 14

**ABILITY OF ACEMANNAN TO REVERSE
MEASLES VIRUS INFECTION IN VERO CELL CULTURE**

5 VERO cells were incubated with medium containing 40 TCID₅₀/ml of measles virus for various periods of time (0.5 to 6 hours) prior to the addition of 5 mg/ml of acemannan. Incubation with acemannan after cells were exposed to the measles virus did not protect the VERO cells from infection.

10 VERO cells were incubated for 0.5 to 6 hours with medium containing 40 TCID₅₀/ml of measles virus. The VERO cells were then washed with fresh medium to remove any unbound virus. Medium containing 5 mg/ml acemannan was then added to the cultures, and the cultures were examined for cytopathology after five days.

15 Results of this experiment are shown in Table 13:

Table 13

20 **EFFECT OF BRIEF INCUBATION OF VERO CELLS WITH
MEASLES VIRUS FOLLOWED BY ACEMANNAN
TREATMENT**

DATE	DIL	VIRUS DOSE	#	1	2	3	4	AV.	INF.
09/29/86	5.0	OT 20 L/0.5mL	25	25	25	10	21.25		
	5.0	0.5 hr	1	3	10	2	3.5	100	
	5.0	1.0 hr	1	10	9	16	9	16	
	5.0	4.0 hr	8	21	25	7	15.25	42	
	5.0	6.0 hr	x	18	15	4	12.3	71	
11/14/86	5.0	OT 20 L/0.5mL	13	17	17	25	18	58	
		0.5 hr						100	
		1.0 hr							
		4.0 hr							
		6.0 hr							
06/10/87	5.0	OT 20 L/0.5mL	100	100		100	100		
	5.0	0.5 hr	8	8	10	9	8.75	14	
	5.0	1.0 hr	10	8	9	11	9.5	15.5	
	5.0	4.0 hr	25	15	25	30	23.75	38	
	5.0	6.0 hr	24	24	25	31	26	42	

Average of two assays for graph 0t = 100-

0.5 hr = 15-

1.0 hr = 28.8-

4.0 hr = 54.5-

6.0 hr = 50-

A lower infection rate was noted in the half-hour and 1-hour acemannan pre-incubation cultures. No clinically significant protection of VERO cells was noted in cultures pre-incubated for longer periods with acemannan.

5 VERO cells pre-incubated with measles virus were not significantly protected from infection by addition of 5 mg/ml of acemannan after the infection period had ended.

Example 15

10 PROJECT TO DETERMINE THE EFFECTIVENESS OF ACEMANNAN ON THE INDUCTION OF A PROTECTIVE IMMUNE RESPONSE IN COMMERCIAL POULTRY

15 Nationally, losses from disease and management related problems cost the poultry industry in excess of \$2 billion annually. Infectious agents such as infectious bursal disease virus (IBDV), a retrovirus that induces mortality and/or morbidity associated with immunosuppression, cause severe economic losses to the poultry industry. IBDV specifically targets precursor B-cells in the bursa of Fabricius leading to selective destruction of the humoral arm of the immune system.
20 This causes an immunosuppressed state akin to Acquired Immune Deficiency Syndrome (AIDS).

The poultry industry routinely vaccinates flocks against IBDV by oral administration of live virus or by subcutaneous injection of inactivated virus. Although both methods of
25 vaccination may effectively elicit an immune response, inherent problems associated with the use of vaccines are introduced. Live virus vaccines are more effective in the elicitation of a protective immune response to a specific strain, but the virus itself may revert to virulence, or replication of the vaccine strain may cause transient immunosuppression leading to
30 increased susceptibility of the flock to secondary pathogens. Killed virus vaccines do not have the same problems as those associated with live virus vaccines, but immune responsiveness is diminished and is dose-dependent. Numerous alternatives to
35 vaccination that involve complicated high-tech solutions are being evaluated, but directed modulation of the immune

response by inclusion of an additional component in a killed-virus vaccine represents a potentially simple solution.

5 Acemannan, on the basis of preliminary observations, acts as an immunomodulator, and this project was designed to determine whether this compound stimulates the immune response to a killed infectious IBDV vaccine.

A. Animals

10 Chicks hatched from eggs purchased from SPAFAS, Inc. were used for all experiments. Eggs were hatched, and day-old chicks were placed in Horsfall Units.

B. Antigen

 BursaVac K (oil emulsion) - acemannan used: Lot #80226-001; resuspended at 1 or 2 mg/ml (see experimental design)

15 **C. Experimental Design:**

Study #1 (Group 1). For Study #1, 25 2-week-old chicks were divided into five groups. The chicks in each group were vaccinated as follows:

 Group 1 - control, sham inoculated

20 Group 2- inoculated subcutaneously over the back with 0.5 ml of oil emulsion vaccine

 Group 3 - inoculated subcutaneously with 0.25 ml of oil emulsion vaccine (Bio-Burs K; Key Vet., Gainesville, GA) mixed with the 0.25 ml of acemannan (0.5 mg/ml) suspended in water (1:1)

25 Group 4 - inoculated orally with 0.5 ml of microcapsules suspended in acidic water

 Group 5 - inoculated orally with 0.5 ml of microcapsules suspended in acidic water with 0.5 mg of acemannan

30 Study #2 (Group 2). For Study #2, 117 1-week-old SPF chicks were divided into six groups. The chicks in each group were vaccinated as follows:

 Group 1 - control, sham inoculated

35 Group 2 - inoculated subcutaneously over the back with 0.5 ml of acemannan (2 mg/ml) suspended in water

Group 3 - inoculated subcutaneously over the back with 0.5 ml of oil emulsion vaccine (Bio-Burs K; Key Vet., Gainesville, GA)

5 Group 4 - inoculated subcutaneously over the back with 0.25 ml of oil emulsion vaccine mixed with 0.25 ml of acemannan (1mg/ml) suspended in water (1:1)

Group 5 - inoculated subcutaneously over the back with 0.25 ml of oil emulsion vaccine mixed with 0.25 ml of acemannan (2 mg/ml) suspended in water (1:1)

10 Group 6 - inoculated subcutaneously over the back with 0.5 ml of oil emulsion vaccine and over the femoral region with 0.5 ml of acemannan (2 mg/ml) suspended in water

For both studies serum was collected from each chick at weekly intervals, and serum IBDV ELISA titers were determined using commercially available AgriTech IBDV ELISA kits. FlockChek software, a program marketed by AgriTech Inc., was also used in determining titers.

D. Results

20 Chicks exhibited no discomfort or side effects as a result of subcutaneous or peroral administration of acemannan suspended in water or oil emulsion.

For Study #1 (Group 1) mean ELISA titers are presented through the sixth week following vaccination in Table 14:

25 Table 14
IMMUNOSTIMULATORY EFFECTS OF ACEMANNAN:
STUDY #1

	<u>IBDV ELISA TITERS</u>		<u>DAYS POST-VACCINATION</u>						
	Present	Antigen	0	7	14	21	28	35	42
30	Group								
	#1	Cont	0	0	0	0	7	107	191
	#2	Em	0	0	54	372	556	218	4983
	#3	Em&Ca	0	5	231	1142	2276	4508	3101
	#4	Mic	0	0	0	2	5	61	127
35	#5	Mic&Ca	0	0	1	0	13	150	0

Two weeks after primary vaccinations, titers to IBDV started to rise in chicks treated with oil emulsion or oil emulsion supplemented with acemannan. Chicks treated with the oil emulsion vaccine supplemented with acemannan had an overall mean titer approximately 3.9 times higher than those vaccinated with oil emulsion vaccine. Three weeks after vaccination the chicks were revaccinated, with each chick receiving the same antigen mixture presented in the primary vaccination. One week after secondary vaccination, the difference in mean titer ratio had increased to approximately 4.1. Two weeks after the secondary injection, when mean titers for both groups had reached their peak, the ratio fell to approximately 2.1. By 3 weeks after secondary vaccination, mean titers for both vaccinated groups had begun to decrease, but the decrease in titer for chicks vaccinated with oil emulsion alone was more precipitous, with a drop in titer of 55% as compared to 31% for chicks vaccinated with oil emulsion supplemented with acemannan. Maintenance of the higher titer in birds treated with oil emulsion supplemented with acemannan appears due to prolonged immunostimulatory actions of acemannan.

Three weeks after the secondary vaccination, chicks from the oil emulsion vaccine group (#2) and the oil emulsion vaccine supplemented with acemannan group (#3) were redivided into two groups (A and B). Group A chicks were challenged with the homologous live vaccine strain, and Group B chicks were challenged with a virulent field strain. Three days after challenge, all chicks were necropsied. There was no effect on the immune system in Group A chicks challenged with the vaccine strain. But all Group B chicks had lesions as demonstrated by histopathology. These were the expected results, but if chicks given only a primary vaccination had been challenged, it is likely that a greater preponderance of lesions in chicks given only the oil emulsion vaccine would have been seen. If the chicks had been vaccinated with the live virus vaccine, lesions in the lymphoid organs would have been seen in chicks resistant to homologous virus challenge.

80

For Study #2, group sizes and the vaccination protocols were changed. As may be seen from Table 15, results were inconsistent:

Table 15

5

IMMUNOSTIMULATORY EFFECTS OF ACEMANNAN: STUDY # 2

10	<u>IBDV ELISA TITERS</u>		<u>DAYS POST-VACCINATION</u>			
	Present					
	Group	Antigen	0	7	14	Std. Dev.
	#1	Cont	0	11	1	S.D. 0
	#2	Ca(0.5mg)	11	37	1	S.D. 0
	#3	Em	21	11	181	S.D. 571
15	#4	Em&0.25mgCa	46	0	5	S.D. 11
	#5	Em&0.5mgCa	188	0	279	S.D. 824
	#6	EmRt&0.5mgCaLt	36	79	504	S.D. 842

20 Differences in the birds were initially noticed two weeks after injection. There were more runts than would be expected, and some of the sites where the chicks were banded appeared to be infected; they had pressure necrosis, which would result in toxin release, in addition to secondary bacterial infection. In an effort to circumvent the latter problem the chicks were rebanded and treated with a topical antibiotic. However, the problems described would probably cause overall immunosuppression, thus voiding the results of this study. Therefore, the experiment was terminated.

30 In spite of the negative factors associated with Study #2, acemannan caused an overall stimulatory effect of the immune system, i.e., as an enhanced immune response to test antigens administered at sites remote from the site of acemannan administration. Although the initial impression was that acemannan had to be mixed with the oil emulsion vaccine, it appears that an enhanced immune response was elicited when the antigen and acemannan were presented separately as well.

This result allows for exploration of alternative vaccination methodologies and applications for this compound.

5 Acemannan has adjuvant properties. It increases the persistence or effective presentation of IBDV antigen within the body, possibly leading to release of lymphokines and an enhanced lymphocyte response.

Example 16

ACEMANNAN USED FOR THE TREATMENT FOR MALABSORPTION SYNDROME

10 Malabsorption syndromes in man cause a wasting condition that can eventually result in death. Specific human syndromes such as sprue and celiac disease can be ameliorated if certain grains containing complex polysaccharides and enzyme-inhibiting peptides are withdrawn from the diet. The
15 result of this diet change is to reduce the symptoms. However, a major physiological problem remains for the patient; maturation of small bowel intestinal mucosa is arrested due to inhibition in synthesis of glycoproteins essential for cell maturation. This failure of small bowel interaction reduces
20 absorption surface and further results in failure to absorb essential amino acids, fatty acids, minerals, vitamins and other critical molecular substances present in the diet.

25 A 56-year-old male who had lost over 40 pounds from chronic gluten-sensitive sprue had a rapid reduction in chronic diarrhea followed by progressive weight gain after taking oral acemannan estimated at 500 to 800 mg/day.

30 Mannose is required for glycoprotein synthesis. Providing additional mannose in a diet predictably shifts the velocity of K_m , increasing the rate of glycoprotein synthesis. Enzyme synthesis is promoted by the availability of the critical mannose substrate that fosters ribosomal/glycoprotein synthesis by mannose-metabolizing enzymes. This increase in glycoprotein synthesis and availability results in small intestine mucosal cell maturation and reduction in symptoms associated with sprue
35 and celiac disease. In addition, this thermodynamic shift in glycoprotein synthesis has applications to other categories of disease for which no effective existing therapy exists.

Example 17

**ACEMANNAN AS A TREATMENT FOR THE SYMPTOMS
ASSOCIATED WITH MULTIPLE SCLEROSIS**

5 Multiple sclerosis (MS) is a neurological disease of
unknown etiology and no effective treatment. Analysis of
patient data and demographics indicate the disease is most
likely initiated by an infectious agent, probably of viral origin.
Analysis of central nervous system lesions, spinal fluid and
serum suggests that an autoimmune component is also present.
10 This autoimmune response results in myelin sheath
degradation.

A 36-year-old patient who had suffered from multiple
sclerosis for more than 6 years and had been bedridden for 4
months was treated with steroids after which walking in the
15 house was possible with the aid of a walker. A wheelchair was
needed for travel outside the home. The attending physician
advised the patient that without chemotherapy (including
treatment with cytoxan), the patient would return to the
bedfast state within 6 months.

20 The patient elected to discontinue all prescribed therapy
and began taking approximately 500 mg oral acemannan daily.
The patient observed no change in the status of the disease
until about 10 weeks had elapsed at which time she reported
feeling better than at any time in the previous year. Two
25 weeks later she was able to walk longer distances using the
walker and in one more month was able to walk with the use of
only a cane. By the time she was to have been bedridden (as
predicted by her physician), she was able to shop several hours
at a time using a cane or walker.

30 The patient has maintained this level for more than 10
months while continuing to consume about 500 mg acemannan
per day with no other concurrent therapy.

35 In 1986, patient F.G. a 57-year-old female presented with
a history of leg weakness, progressive loss of voice and multiple
other neuromuscular symptoms. At Johns Hopkins Medical
School, MS was diagnosed with NMR confirmation. The patient

was started on 800 mg/day oral acemannan and an extensive exercise program.

Six weeks after therapy initiation, she was able to go on an ocean cruise with limited physical support. The patient's voice progressively strengthened and other symptoms improved. At 6 months she reported that her neurologist indicated that plaques visualized by NMR techniques had regressed. The patient continues to experience remission of the symptoms associated with MS.

Example 18

ACEMANNAN USED AS AN ANTIVIRAL AGENT IN A PLANT

Acemannan was evaluated as an antiviral agent against the LaFrance virus, a major problem in the mushroom farming industry. The compost used was prepared by a modification of the method of Flegg et al. LaFrance virus-infected *Agaricus bisporus* M8 spawn was added to prepared compost at 3% of dry matter. The spawned trays were covered with plastic and incubated for 14 days at 24°C. Acemannan was added to spawned compost in a range of doses from 0.01% to 2% (calculated on a dry weight basis) and placed into 11" x 7" trays at 1.0 lb dry matter/tray. The material was mixed evenly with the compost by adding both components to the sampling bag and mixing thoroughly. Spawned, treated compost was turned and overlaid with sphagnum peat moss and incubated for a further 7 days at 24°C; the overlay material was then gently mixed, the plastic replaced, and the trays incubated an additional 10 days. The plastic was then removed and the trays incubated for an additional 7 days at 18°C in an environmental chamber. Mushrooms were harvested at weekly intervals thereafter for three weeks.

Sporophores were analyzed for double stranded (ds) viral RNA by homogenization in 20 ml STE (1.0 M NaCl; 0.5 M Trizma base, pH 8.0; and 0.01 M EDTA), 20 ml LiCl, and 10 ml 10% SDS. The dsRNA was extracted in phenol and the aqueous phase was passed through a Bio-Rad LC column containing Whatman CF-11. The cellulose-bound dsRNA was washed and then eluted

with STE. After precipitation with ethanol and resuspension in citrate solution, an aliquot was characterized by agarose gel electrophoresis. The dsRNA patterns were visualized by ethidium bromide staining. A reduction in dsRNA was shown in the sporophore analyzed from experimental trays containing 0.01% to 1.0% acemannan as compared to untreated controls.

Example 19

ACEMANNAN USED AS A TREATMENT FOR CHRONIC FATIGUE SYNDROME

Acemannan has been shown to affect chronic viral syndromes in humans. A 41-year-old female with a 2 year history of markedly debilitating "chronic fatigue syndrome" (CFS) and elevated Epstein-Barr viral titers reported that taking 800 mg/day of acemannan orally for 6 months resulted in complete relief of lethargy. After three excellent months without symptoms, the patient discontinued oral acemannan and there was a slow return of tiredness with fatigue. Resumption of acemannan rapidly alleviated the symptoms of the syndrome.

A physician's sister had a prolonged period of chronic fatigue syndrome with elevated Epstein-Barr antibodies. Multiple clinical evaluation and therapeutic regimens had no effect. The patient started consuming 800 mg acemannan daily and reported a marked improvement followed by elimination of symptoms after 2-3 months of acemannan therapy.

Example 20

COMBINATION OF RADIATION, CHEMOTHERAPY AND ACEMANNAN FOR THE TREATMENT OF A TUMOR OF EMBRYONIC TISSUE ORIGIN

Patient W.H. at the age of 41 presented at a medical center with severe chest pain. Radiographs suggested a mediastinal mass of possible vascular origin and the patient was transferred to a cardiovascular center. There it was determined that a mass extended from the low neck region to the diaphragm, grew between the lungs and involved the base of the heart. Biopsy disclosed a malignant embryonic sinus tract tumor. Treatment with oral acemannan, (approximately 500

mg/day with radiation and chemotherapy) was instituted. Six years past therapy, the patient has a normal chest x-ray and lives a normal, active life. A review of the literature disclosed 20 such tumors with 100% fatality 9 to 12 months post-diagnosis.

Example 21

MULTI-DRUG COMBINATION CHEMOTHERAPY AND ACEMANNAN TREATMENT OF A HEPATIC TUMOR

Patient M.A. presented with the chief complaint of inability to zip up his pants or get his belt around his abdomen. Computer axial tomographic (CAT) scans in April 1988 revealed multiple tumors in the liver which extended to the urinary bladder. The liver was largely replaced by over 20 tumor masses up to 10 cm in diameter. A life expectancy of 4 to 6 weeks was given. The patient had been on 800 mg/day oral acemannan for HIV-1 infection. A multiple chemotherapeutic treatment was initiated and the acemannan was continued. The patient had minimal side-effects and toxicity usually associated with cancer chemotherapy. Evaluation at 3 months included a CAT scan that revealed an estimated 60% reduction in tumor mass. At 6 months, 85% reduction in tumor mass was estimated. Only minimal tumor was noted at 12 months, and at 24 months only small scars with questionable tumor mass remained in the liver. All clinical laboratory work was normal and the patient is currently doing well.

Example 22

ACEMANNAN TREATMENT OF SKIN TUMORS ASSOCIATED WITH HIV

Patient S.G. presented with two black lesions, palpable on his arm that had been previously diagnosed by biopsy as Kaposi's sarcoma. Acemannan gel with 5% DMSO was topically applied to the skin masses on the arm while similar masses on other parts of the body were not treated. Reexamination at weekly intervals revealed noticeable flattening and depigmentation of the lesions. Sixty days after therapy was begun, only flat scarred areas remained. Subsequent treatment of other lesions on the same patient showed the same results.

Patient T.P.D. presented with a palpable ankle lesion with pigmentation of classic Kaposi's sarcoma. The lesion was subcutaneously injected with 1 cc recombinant alpha interferon (Roche). The size and pigmentation were improved by 3 days. Topical acemannan gel on a bandage was applied and, by the end of 1 week, no evidence of a lesion remained. There was no scarring or alteration of pigmentation.

Example 23

ACEMANNAN TREATMENT OF PREMALIGNANT SKIN LESIONS

Subject W.B., a balding physician, had numerous solar keratoses over sun-exposed skin. Two weeks of nightly applications of acemannan gel to these lesions resulted in removal of the scales, crusts and skin irregularities that were pre-malignant in appearance. This response has been noted in many other mature patients.

Example 24

ACEMANNAN TREATMENT OF EDEMA ASSOCIATED WITH CANCER SURGERY

In January 1984, patient J.J., a 32-year-old male with unsuccessful surgical resection of a pharyngeal primary tumor, radical neck dissection, radiation and chemotherapy was in unmanageable pain due to total occlusion of the larynx and esophagus. Due to lymphatic blockage, the head was approximately twice normal size and edema had obliterated all facial features. Life was sustained by a feeding gastroscopy and a tracheotomy. Topical acemannan gel (CDWG 0.025%) was applied copiously over the entire head, neck and shoulders every 8 hours (TID). By the third day the edema was noticeably reduced and by the tenth day the excess tissue fluid was gone. Between the 14th and 16th day there developed fluctuant areas in the neck base, angles of the jaw and behind the ears. The skin opened and necrotic tissue began to exude from the areas of former hard, infiltrative, nodular tumor. The patient began to cough up masses of gray-white degenerating tumor. Multiple transfusions were given for the massive hemorrhage which ensued. Slowly, the patient regained the

ability to speak, eat soup and breathe through the mouth and nose.

Example 25

COMBINATION 5-FLUOROURACIL AND ACEMANNAN CANCER TREATMENT

5 Patient C.M. had an abdomino-peritoneal resection of low
rectal adenocarcinoma with high mesenteric lymph node
metastasis. The patient refused radiation therapy but elected to
accept weekly 5-fluorouracil (5-FU) IV infusions and 800 mg
10 oral acemannan/day. The patient did not suffer the oral ulcers,
severe fatigue or nausea with vomiting usually associated with
5-FU treatment. After an extensive evaluation by isotopic scans
and computerized tomography (CAT), the patient had no
detectable adenocarcinoma at 24 months post-surgery and
15 continues to be normal.

Example 26

MULTI-DRUG COMBINATION CHEMOTHERAPY AND ACEMANNAN CANCER TREATMENT

20 Patient H.H. had adenocarcinoma of the colon with a
resection followed by discovery of rising CEA tumor nodules
and CAT scan evidence of a liver nodule. Treatment with oral
acemannan (800 mg/day) was begun, along with weekly IV
injections of 5-FU (500 mg) dicarbazine (50 mg), and
acemannan orally (800 mg). Progressive reduction in tumor
25 size and CEA values occurred with no evidence of side effects or
biochemical or hematological toxicity.

In 1990, patient V.G., a 66-year-old male, presented
following total pneumonectomy with bone and liver metastasis
for squamous carcinoma of bronchiogenic origin. Alkaline and
30 all liver enzymes were elevated more than triple the upper
limits of normal. One month's therapy of 500 mg 5-FU and 50
mg dicarbazine IV weekly and 800 mg oral acemannan daily
resulted in reduction of the alkaline phosphatase and liver
enzymes to half their pre-treatment levels along with
35 improvement of the patient's general condition.

Example 27
MULTI-DRUG COMBINATION CHEMOTHERAPY
AND ACEMANNAN CANCER TREATMENT WITH
ANTI-MALE HORMONE THERAPY

5 Patient J.R., a 72-year-old male, presented post-surgery
and post-radiation with metastatic adenocarcinoma of the
prostate with rising acid phosphatase (PAP) and prostate
specific antigen (PSA). The patient was started on oral
10 acemannan (800 mg/day) 5-FU (500 mg) and dicarbazine (50
mg). The rise in tumor markers plateaued, reaching a high of
15 units for PAP and 186 U. for PSA. The anti-hormonal agent
Eulexin was added to the regimen. The PAP dropped within 60
days to 3.0 and the PSA to 15. This response was accomplished
15 with no toxicity or side effects at any stage. This patient
continues to be monitored while the total regimen is continued.

Example 28
ACEMANNAN TREATMENT OF VENOMOUS ANIMAL BITES

20 Acemannan had been shown to alter the body's response
to antigens, toxins, allergens and "self" antigens. Two cases of
acemannan gel were sent to Swangi Province in Southern China.
The Red Cross received the product to be used for burns, bed
sores, stasis ulcers, and diabetic skin ulcerations.
25 Approximately 1 year later the head of the Red Cross wrote to
confirm that acemannan gel had been a useful treatment of the
above conditions; additionally, he reported that it was the best
treatment they had ever used for water snake bite, a common
occurrence in the manually-worked rice paddies. Snake bites
30 often become infected and are non-responsive to antibiotics;
resulting necrosis from profound ischemia in soft tissue causes
considerable loss of skin and muscle tissue.. Occlusive dressing
of wounds with acemannan gel eliminated the unmanageable
infections and apparently helped restore capillary circulation to
35 surrounding tissue. This treatment preserved digits, muscles,
nerves and soft tissue.

Example 29**ACEMANNAN-TREATED CULTURES OF FIBROBLASTS
REVERT TO NEONATAL MORPHOLOGY AND FUNCTION**

5 Acemannan-treated cultures of fibroblasts obtained from
a 60-year-old man revealed a change in the morphology of
these aging cells. This change appeared to evidence a reversal
in the aging process in these human cells in vitro. Longer-term
fibroblast cultures treated with acemannan (1mg/ml) in the
culture medium resulted in expression of biochemical and
10 morphological characteristics of neonatal cells.

In 1989, a physician examined biopsies of facial skin from
a surgery specimen submitted to the pathology department at
Duke University. The biopsy was from Mohl's surgery
performed for treatment of skin cancer. Acemannan gel was
15 applied post operatively. The specimen exhibited an unusual
pattern of necrobiosis with destruction of damaged collagen
fibers and rapid regeneration of young collagen fibers by
enlarged fibroblasts. The result was rapid remodelling of the
structures in this aged skin specimen.

20 In 1990, the same physician examined thymuses from
dogs given acemannan. These thymuses were 2-6 times larger
than the thymuses of the control dogs. Microscopically the
thymuses from the treated dogs were hypercellular with
evidence of hyperplasia and activation of thymocytes.
25 Increased numbers of T-lymphocytes and "nurse-cell" indicated
an apparent expansion in T-lymphocyte clones. The induction
of thymus activity and fibroblast activity in tissues of
acemannan-treated animals would result in the return to
function of age-depleted tissues.

30

Example 30**ACEMANNAN EFFECT ON CHOLESTEROL LEVELS
IN ANIMALS AND HUMANS**

Male dogs given 855 mg/kg/day of acemannan had a
statistically significant reduction in serum cholesterol levels
35 which was observed during a 91-day toxicity study. A similar
effect was noted in normal male volunteers given doses of
acemannan ranging from 400 mg to 3200 mg per day. An

important effect of acemannan therapy which was observed was the statistically significant reduction in serum cholesterol level toward normal values for these subjects. Upon entry into the study, the mean cholesterol concentration of the 24 subjects was 189 mg/dl; it was 174 mg/dl upon exit. Statistical analysis using the "CRUNCH" Software version of the Wilcoxon Signed-Ranks Tests indicated >98% probability that the drop in cholesterol was not due to chance variation. Cholesterol concentrations in seven of the 24 patients decreased more than 20 mg/dl in 6 days of treatment, and therefore it is difficult to attribute this effect to a simple dietary improvement during the subjects' controlled residence during the study.

Example 31

ACEMANNAN TREATMENT OF INJURY RESULTING FROM PLANTS

Two competition hunters who had a supply of acemannan for veterinary use took it with them on a trip to Africa. After an episode of diarrhea, the hunters decided to take the acemannan themselves. The acemannan was taken at an 800 mg/day dosage level. The hunters reported that they experienced less diarrhea than other hunters. Also, because of briars in the bush, the hunters suffered numerous cuts on their arms and legs. The hunters taking acemannan reported that their cuts and scratches seemed to heal virtually overnight. No redness or inflammation developed. All abrasions were totally healed by the time they flew back to the U.S. Other members of the hunting party suffered serious infections of their cuts and abrasions requiring visits to their physicians for systemic and topical antibiotic therapy. The two hunters taking acemannan had no infections and no scarring.

Example 32

ACEMANNAN TREATMENT OF ALLERGIES RESULTING FROM HYPERSENSITIVITY TO PLANTS

Acemannan was used to ameliorate the inflammatory effect of plant allergens. Subject H.R.M., with a known family history of seasonal hayfever, experienced annual episodes of itching, burning, congestion and watering of mucosal

membranes. Starting in 1988, it was found that 800 mg/day oral acemannan for 5 days virtually eliminated hayfever symptoms including sinus headaches produced by the swollen nasal mucosa. In 1989, it was found that acemannan gel applied topically to the mucosa of the eyes and nasal passages at bedtime and every 8 hours thereafter resulted in a similar effect and benefit to H.R.M.

Similar results have been seen with topical administration of acemannan to poison ivy lesions in humans and animals. The severity of and the healing time for the lesions were significantly reduced.

Example 33

ACEMANNAN TREATMENT OF ALLERGIES RESULTING FROM HYPERSENSITIVITY TO CHEMICALS

Acemannan was used to ameliorate the inflammatory effect of chemical allergens. Subject T.R., a professional painter, was on the verge of quitting his profession due to wheezing and bronchitis induced by vapors from his paints and solvents. After taking 800 mg/day oral acemannan for five days, his symptoms were relieved. The patient continues to consume 800 mg/day of oral acemannan before work each day and is able to continue painting.

Example 34

ACEMANNAN TREATMENT OF SYMPTOMS ASSOCIATED WITH ASTHMA

A 76-year-old male, T.T., with a 72-year history of asthma was taking 800 mg acemannan daily for an unrelated condition. After 1 year of therapy, T.T. told the attending physician he had not used his aerosolized bronchodilator for over 1 year and a significant amount was still in the unit. His wife stated that he had averaged 2 units per month for 15 years and had used a hand aerosolizer for 50 years before that for chronic asthma. The patient continues to take 800 mg acemannan daily and no longer has wheezing or chronic bronchitis.

Example 35**ACEMANNAN TREATMENT OF SYMPTOMS ASSOCIATED
WITH CYSTIC FIBROSIS**

5 A college-age female with 6-month history of cystic
fibrosis syndrome reported an abrupt return of energy within 2
weeks of instituting oral acemannan therapy at a dose of 800
mg/day.

Example 36**ACEMANNAN TREATMENT OF CYTOMEGALOVIRUS
INFECTION AS A RESULT OF HIV INFECTION**

10 A 27-year-old HIV-1-positive male, M.M., had substernal
pain for 2 months unrelieved by medications. An
15 esophagoscopy disclosed an erosion of the distal esophageal
mucosa. Histopathological staining of biopsies disclosed
cytomegalovirus organisms in the epithelial cells. Three days of
1000 mg oral acemannan administered as a lozenge eliminated
all symptoms.

Example 37**ACEMANNAN TREATMENT OF SEQUELA TO
A RHEUMATIC FEVER EPISODE**

20 A 25-year-old female, S.M., had the acute onset of
25 arthritis, tendonitis, joint edema, leukocytes, and elevated
sedimentation rate following a sore throat caused by an acute
episode of post-streptococcal rheumatic fever. The ASO titer
was markedly elevated. Her sisters and mother had histories of
severe, multiple bouts of acute rheumatic fever with
30 incapacitation lasting for up to a year.

 The patient was administered 800 mg/day oral
acemannan. Sedimentation rate and white count were normal
by week 6 of therapy and all clinical symptoms were gone. The
patient returned to a manual labor job requiring high dexterity
35 after 8 weeks of therapy.

Example 38
ACEMANNAN USED IN THE TREATMENT
OF AUTOIMMUNE DISEASE

5 A 21-year-old female (E.M.) with a history of
pancytopenia, over 2 years progressive anemia, leukopenia and
thrombocytopenia presented for treatment in June 1988. She
related a history of failure to respond to therapy offered at
eight major medical centers in the U.S. Bone marrow transplant
had been offered as the next step in therapy. When first
10 examined, the patient had bruising, petechiae, fatigue, low
hemoglobin (6.1 gm%) and low platelets (20,000-25,000/mm³)
and total white count of 1,500 cells/mm³. Antibody to her own
white cells was reported by a specialty clinical pathology
laboratory. The patient was placed on 800 mg of oral
15 acemannan for 60 days. Minor improvement in laboratory
values was noted and her fatigue was minimally reduced. A
hematologist was enlisted to administer low-dose prednisone
and horse antithymocyte globulin. The former had previously
been ineffective. By October 1988 the patient's hemoglobin was
20 over 10 gm%, white blood count was 3,500 cell/mm³ and
platelets were 60,000. By mid-1989, 800 mg/day of oral
acemannan was resumed for 6 months. In January 1990 the
patient reported hemoglobin 12.7 gm%, platelets 120,000 and
white blood count 5,200 cells/mm³. The patient is not on any
25 medication currently and is a professional dancer-
choreographer in graduate school.

Example 39
ACEMANNAN TREATMENT OF SYSTEMIC
LUPUS ERYTHEMATOSUS

30 A patient with systemic lupus erythematosus was treated
by a New York physician with 800 mg/day of oral acemannan.
The physician reported that all symptoms diminished and
laboratory values markedly improved after 8 weeks of
acemannan therapy. Continued acemannan therapy appeared
35 to control the symptoms associated with this patient's condition.

Example 40**ACEMANNAN TREATMENT OF ACUTE
RHEUMATOID ARTHRITIS**

5 A physician reported that a series of patients with acute
rheumatoid arthritis (RA) had elevated RA latex levels and
sedimentation rates. After 6 to 8 weeks of 800 mg/day of oral
acemannan, the patients had significantly reduced symptoms
and markedly improved clinical laboratory values.

Example 41

10 **ACEMANNAN TREATMENT OF
CHRONIC RHEUMATOID ARTHRITIS**

A 65-year-old female, B.L.H., with a 20-year history of
chronic RA, deformed joints, subcutaneous nodules and
tendinous nodules suffered with chronic pain. When the patient
15 was seen in the fall of 1988, she had been given numerous
treatments including gold shots with little benefit. Oral
acemannan (800 mg/day) was recommended. No benefit was
reported for 6 months. In mid-1989 the patient reported
diarrhea if acemannan was taken more often than twice weekly,
20 but symptoms of arthritis were improving. In time, 800 mg
acemannan three times per week was tolerated and symptoms
of RA noticeably improved. In January 1990 the patient
reported that she had experienced her best 6 months of life in
the last 15 years. The effort required and the pain associated
25 with her daily tasks were markedly reduced.

Example 42**ACEMANNAN AND ANTIDEPRESSANT THERAPY
OF DEPRESSION AND ANXIETY**

A psychologist gave 800 mg of oral acemannan per day to
30 patients who had failed to respond to psychotherapy and
antidepressant drugs taken for severe depression and anxiety.
He reported that by the end of the week he could observe that
the patients' emotions had become more stable and that there
was a remarkable improvement in attitude for the first time
35 since the patients had been under long-term observation.

Example 43**ACEMANNAN TREATMENT OF FELINE LEUKEMIA**

5 Feline leukemia (FeLV) is a retrovirus (class oncovirus) infection in which cats present with diverse clinical signs. Infection of the lymphoreticular system is predominant with the majority of animals dying within 3 years. Current treatment for this disease is symptomatic; no cure exists.

10 Forty-five cats with end-stage FeLV disease were treated by intraperitoneal injection of acemannan weekly for six treatments and observed for 6 more weeks. The cats were monitored by weekly examinations during the treatment period. In addition, laboratory data were obtained at entry, mid-study and at exit from the study.

15 Sixty-seven percent of the treatment animals improved during the study. The average survival time of animals not responding to acemannan therapy was less than 28 days.

Example 44**ACEMANNAN AND ANTIFUNGAL DRUG TREATMENT OF FUNGAL INFECTIONS ASSOCIATED WITH HIV**

20 Three HIV-1 patients' records reveal a similar pattern in that these patients developed hairy leukoplakia and/or monilial plaques and/or ulcers of the oral cavity. Their conditions were usually extensive and painful. The use of Ketaconazole had improved the condition of some patients, but others were
25 unresponsive. Within 1 week of adding 800 mg/day oral acemannan to their therapy, the patients reported elimination of these mucocutaneous lesions. Taking acemannan and Ketaconazole for 3 to 5 days cleared the outbreak for weeks to months. Continued acemannan administration eliminated or
30 reduced outbreaks of the mucocutaneous infections.

Example 45**ACEMANNAN AND ANTIPROTOZOAL DRUG TREATMENT OF PNEUMOCYSTIS CARINII INFECTION ASSOCIATED WITH HIV**

35 An HIV-1 study patient receiving 800 mg/day oral acemannan was admitted to an Arkansas veterans hospital for x-ray diagnosis-compatible and sputum-proven Pneumocystis

carinii pneumonia (PCP). In the experience of the V.A. Hospital, HIV-1 patients with PCP take 2 or more weeks to respond to therapeutic measures, if they ever respond. The patient responded to 1 week of aerosolized pentamidine and continued acemannan therapy. He was dismissed symptom-free.

Example 46

**ACEMANNAN AND ANTIBIOTIC TREATMENT
OF CRYPTOSPORIDIOSIS INFECTION
ASSOCIATED WITH HIV**

An HIV-1 patient with chronic diarrhea and weight loss was shown to have the typical acid-fast spores in his stool diagnostic of cryptosporidiosis. The combination of 800 mg/day oral acemannan and 250 mg Q.I.D. ansamycin (rifbutin) daily for 2 weeks rendered the patient free of diarrhea with resulting weight gain.

Example 47

**ACEMANNAN AND ANTITUBERCULAR DRUG TREATMENT
OF RESISTANT HUMAN TUBERCULOSIS ASSOCIATED
WITH HIV**

HIV-1 positive patient S.G. suffered progressive weight loss and low-grade fever of unknown etiology. Discovery of retroperitoneal lymphadenopathy and biopsies of the mass eventually revealed a culture of human tuberculosis. The patient had been on 800 mg/day acemannan daily. Institution of antitubercular therapy comprised of 300 mg/day isoniazid, 600 mg/day rifampin, and 1000mg/day ethambutol resulted in the patient's becoming afebrile within 24 hours and gaining weight within 10 days.

Example 48

**ACEMANNAN AND ANTITUBERCULAR DRUG TREATMENT
OF RESISTANT AVIAN TUBERCULOSIS INFECTION IN
HUMANS ASSOCIATED WITH HIV**

An HIV-1 patient had continuous diarrhea that eventually was shown by smear and culture to be mycobacterium avian intercellular tuberculosis (MAI). No agent is known to be effective; however, ansamycin was provided by C.D.C. In combination, 250 mg Q.I.D. ansamycin and 800 mg/day oral

5 acemannan resulted in termination of diarrhea in less than 1 week. Within 2 weeks the patient who was losing weight at a rate of 3 to 4 pounds per week began to gain weight. Fatigue and general weakness decreased. In another HIV-1 patient, C.C., who had biopsy and culture-proven MAI, a similar rapid resolution and negative culture tests were obtained after oral acemannan.

Example 49

10 **ACEMANNAN AND MULTIDRUG CHEMOTHERAPY INCLUDING CISPLATIN CANCER TREATMENT OF BREAST CANCER**

15 A 38-year-old female, J.F., was five years post-mastectomy for duct cell carcinoma of the breast. The patient appeared pregnant due to ascites of peritoneal metastasis. CAT scan evidence of liver and multiple bone sites of lytic tumor were demonstrable. The patient had delayed chemotherapy and was estimated to be 4 to 6 months from death. The patient was told to start acemannan at an oral dose of 800 mg/day and to start the recommended multiple agent cytotoxic chemotherapy (adriamycin, cyclophosphamide, mitomycin-C and 5-FU) as offered by her local oncologist. She was started on weekly IV administration of cisplatin in combination with adriamycin and other agents. The patient suffered no side effects except hair loss and fatigue the day of infusion. Subsequent examinations have demonstrated re-ossification of bone metastasis, elimination of ascites, elimination of palpable abdominal masses, disappearance of the liver mass and weight gain.

Example 50

30 **ACEMANNAN TREATMENT OF CUTANEOUS FUNGAL INFECTIONS**

35 A 40-year-old physician applied acemannan gel to itching, cracked, and burning lesions between and above the bases of his toes. In less than a week, the doctor reported that the response and healing proved acemannan to be the most effective medication he had used in over 20 years of periodic treatment of his chronic athlete's foot. Other patients have reported

similar improvement. Remarkably, some patients who were taking acemannan for other conditions reported improvement of athlete's foot lesions.

Example 51

5

ACEMANNAN TREATMENT OF MARINE ANIMAL STINGS

10

A 40-year-old female who was scuba diving damaged her knee on fire coral. The lesions covered approximately 9 square centimeters of skin surface. The normal clinical course of this sting in humans is intense inflammation for approximately 8 hours followed by delayed healing of the skin wound for 14 days. Application of acemannan gel to the wound for 8 days resulted in complete healing, and scarring was barely detectable.

SUMMARY

Acemannan has been shown to be effective in treating a number of conditions where the principal mechanism of resolution or cure requires intervention by the patient's immune system. Acemannan has direct stimulatory effects on the immune system. In addition, acemannan directly interacts with virus or other infectious organisms, infected cells, and tumor cells to produce changes in their immunologically sensitive surface composition to alter the appearance of these agents and cause them to be recognized by the body's immune system and then destroyed.

It is thus believed that the operation and administration of the present invention will be apparent from the foregoing description. While the method and techniques shown and described have been characterized as being preferred, it will be obvious that various changes and modifications may be made therein without departing from the spirit and scope of the invention as defined in the following claims.

WE CLAIM:

1. The use of an acetylated mannan derivative in the manufacture of a medicament for treating a viral disease.
2. The use according to claim 1, wherein said virus
5 comprises a DNA virus or an RNA virus.
3. The use according to claim 1, wherein said virus comprises Iridoviridae, Poxviridae, Hepadnaviridae, Orthomyxoviridae, Paramyxoviridae, Rhabdoviridae, or Bunyaviridae.
4. The use according to claim 1, wherein said virus
10 comprises Filoviridae, Nodaviridae, Togaviridae, Flaviviridae, or Arenaviridae.
5. The use according to claim 1, wherein said virus comprises Herpesviridae or Retroviridae.
6. The use according to claim 5 wherein said
15 Retroviridae is an HIV virus.
7. The use according to claim 5 wherein said acetylated mannan derivative is acemannan.
8. A method for producing an antiviral effect in a
20 tissue culture infected with a virus, comprising:
administering to said tissue culture an amount of an acetylated mannan derivative sufficient to inhibit the replication of said virus.
9. A method according to claim 8, wherein said tissue
25 culture comprises an animal tissue culture or a plant tissue culture.
10. A method according to claim 8, wherein said acetylated mannan derivative is acemannan.

11. The use of an acetylated mannan derivative in the manufacture of a medicament for treating a tumor.

12. The use according to claim 11, wherein said tumor comprises benign tumor or malignant tumor.

5 13. The use according to claim 11, wherein said tumor comprises tumor of the skin, tumor of soft tissues, tumor of the muscle, tumor of joints, tumor of adjacent soft tissue, tumor of bone, or tumor of cartilage.

10 14. The use according to claim 11, wherein said tumor comprises tumor of lymphoid tissues, tumor of hematopoietic tissues, tumor of the respiratory system, tumor of the alimentary tract, tumor of the liver, tumor of gall bladder, or tumor of pancreas.

15 15. The use according to claim 11, wherein said tumor comprises tumor of the urinary system, tumor of the genital systems, tumor of the mammary gland, tumor of the endocrine glands, tumor of the nervous system, or tumor of the eye.

16 The use according to claim 11, wherein said tumor is a human malignant tumor.

20 17. The use according to claim 16, wherein said tumor comprises acute lymphoid leukemia, acute myeloid leukemia, chronic myeloid leukemia, or chronic lymphoid leukemia.

25 18. The use according to claim 16, wherein said tumor comprises polycythemia vera, myelosclerosis with myeloid metaplasia, multiple myeloma, or primary macroglobulinemia.

19. The use according to claim 16, wherein said tumor comprises Hodgkin's disease, non-Hodgkin lymphoma, skin cancer, or malignant melanoma.

30 20. The use according to claim 16, wherein said tumor comprises head and neck cancer, lung cancer, gastrointestinal

cancer, breast cancer, gynecologic cancer, or trophoblastic disease.

21. The use according to claim 16, wherein said tumor comprises testicular cancer, prostate cancer, renal carcinoma, bladder cancer, endocrine tumor, or brain tumor.

22. The use according to claim 16, wherein said tumor comprises retinoblastoma, neuroblastoma, Wilm's tumor, osteogenic sarcoma, Ewing's sarcoma, or soft-tissue sarcoma.

23. The use according to claim 11, wherein said acetylated mannan derivative is acemannan.

24. A method for inducing the immune system of a plant to substantially eliminate a tumor infecting said plant, comprising:

administering to said plant an amount of an acetylated mannan derivative sufficient to cause the immune system of said plant to inhibit the growth of said tumor.

25. A method according to claim 24, wherein said acetylated mannan derivative is administered directly, or through a water source, of said plant.

26. A method according to claim 24, wherein said tumor comprises a malignant tumor or a non-malignant tumor.

27. A method according to claim 24, wherein said acetylated mannan derivative is acemannan.

28. The use of an acetylated mannan derivative in the manufacture of a medicament for restoring tissue viability in a damaged tissue.

29. The use according to claim 28, wherein said acetylated mannan derivative is acemannan.

30. The use according to claim 28, wherein said tissue damage comprises ulceration or necrosis.

5 31. The use of an acetylated mannan derivative in the manufacture of a medicament for treating an inflammatory bowel disease.

32. The use according to claim 31, wherein said acetylated mannan derivative is acemannan.

10 33. The use of an acetylated mannan derivative in the manufacture of a medicament for treating symptoms associated with multiple sclerosis.

34. The use according to claim 33, wherein said acetylated mannan derivative is acemannan.

35. The use of an acetylated mannan derivative in the manufacture of a medicament for stabilizing emotions.

15 36. The use according to claim 35, wherein said acetylated mannan derivative is acemannan.

37. The use of an acetylated mannan derivative in the manufacture of a medicament for treating traumatic injuries.

20 38. The use according to claim 37, wherein said acetylated mannan derivative is acemannan.

39. The use of an acetylated mannan derivative in the manufacture of a medicament for preventing infection.

40. The use according to claim 39, wherein said acetylated mannan derivative is acemannan.

25 41. The use of an acetylated mannan derivative in the manufacture of a medicament for enhancing therapeutic effect of a known therapeutic agent requiring the aid of an immune system.

42. The use according to claim 41, wherein said acetylated mannan derivative is acemannan.

43. A method for producing an immunoenhancement effect of a vaccine, comprising:

5 adding an acetylated mannan derivative to said vaccine in an amount in the range of from about 0.001 mg to about 10 mg per vaccine dose.

44. A method according to claim 43, wherein said acetylated mannan derivative is acemannan.

10 45. The use of an acetylated mannan derivative in the manufacture of a medicament for reducing inflammatory symptoms associated with an autoantibody disease.

46. The use according to claim 45, wherein said acetylated mannan derivative is acemannan.

15 47. The use of an acetylated mannan derivative in the manufacture of a medicament for reducing symptoms associated with chronic respiratory diseases.

48. The use according to claim 47, wherein said acetylated mannan derivative is acemannan.

20 49. The use of an acetylated mannan derivative in the manufacture of a medicament for delaying the aging process of cells.

50. The use according to claim 49, wherein said acetylated mannan derivative is acemannan.

25 51. The use of an acetylated mannan derivative in the manufacture of a medicament for treating diabetes.

52. The use according to claim 51, wherein said acetylated mannan derivative is acemannan.

53. The use of an acetylated mannan derivative in the manufacture of a medicament for regulating blood cholesterol level.

5 54. The use according to claim 53, wherein said acetylated mannan derivative is acemannan.

55. The use of an acetylated mannan derivative in the manufacture of a medicament for removing plaque formed in blood vessels.

10 56. The use according to claim 55, wherein said acetylated mannan derivative is acemannan.

57. The use of an acetylated mannan derivative in the manufacture of a medicament for reducing inflammation within the nervous system

15 58. The use according to claim 57, wherein said acetylated mannan derivative is acemannan.

59. The use of an acetylated mannan derivative in the manufacture of a medicament for treating parasitic infestations.

60. The use according to claim 59, wherein said acetylated mannan derivative is acemannan.

20 61. The use of an acetylated mannan derivative in the manufacture of a medicament for treating infections.

62. The use according to claim 61, wherein said acetylated mannan derivative is acemannan.

25 63. The use of an acetylated mannan derivative in the manufacture of a medicament for promoting wound healing.

64. The use according to claim 63, wherein said acetylated mannan derivative is acemannan.

65. The use of an acetylated mannan derivative in the manufacture of a medicament for treating the stings, bites and scratches of animals and pricks and scratches of plants.

5 66. The use according to claim 65 wherein the acetylated mannan derivative is acemannan.

AMENDED CLAIMS



[received by the International Bureau on 1 March 1993 (01.03.93);
original claims 1-23,31-34,43,44,57,58,63 and 64 cancelled;
other claims unchanged]

STATEMENT UNDER ARTICLE 19

Applicant's invention pertains to various uses of a polysaccharide substance which is predominantly an acetylated mannan, such as acemannan, or its derivatives.

This application has been carefully considered in connection with the International Search Report. Claims 1-23, 31-34, 43, 44, 57, 58, 63 and 64 have been cancelled.




The cited references are not deemed, either singly or in combination, to teach or suggest the remaining unchanged claims.



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 91/08204

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl.5 A 61 K 31/715											
II. FIELDS SEARCHED <div style="text-align: right;">Minimum Documentation Searched⁷</div> <table border="1" style="width: 100%;"> <tr> <td style="width: 20%;">Classification System</td> <td>Classification Symbols</td> </tr> <tr> <td>Int.Cl.5</td> <td>A 61 K</td> </tr> </table> <p style="text-align: center;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched⁸</p>			Classification System	Classification Symbols	Int.Cl.5	A 61 K					
Classification System	Classification Symbols										
Int.Cl.5	A 61 K										
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table border="1" style="width: 100%;"> <tr> <th style="width: 10%;">Category^o</th> <th style="width: 70%;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 20%;">Relevant to Claim No.¹³</th> </tr> <tr> <td>X</td> <td>Int. Conf. AIDS, vol. 6; no. 2, 1990, M.C. KEMP et al.: "Concentration-dependent inhibition of AIDS virus replication and pathogenesis by acemannan in vitro", page 315, abstract no. 1007, see abstract ---</td> <td>1-66</td> </tr> <tr> <td>X</td> <td>Dissertation Abstracts International, vol. 52, no. 2, August 1991, A.D. CHINNAH et al.: "Evaluation of the antiviral, adjuvant and immunomodulatory effects of a beta-(1,4)-linked polymannose (acemannan)", page 694-B, see abstract --- -/-</td> <td>1-66</td> </tr> </table>			Category ^o	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	Int. Conf. AIDS, vol. 6; no. 2, 1990, M.C. KEMP et al.: "Concentration-dependent inhibition of AIDS virus replication and pathogenesis by acemannan in vitro", page 315, abstract no. 1007, see abstract ---	1-66	X	Dissertation Abstracts International, vol. 52, no. 2, August 1991, A.D. CHINNAH et al.: "Evaluation of the antiviral, adjuvant and immunomodulatory effects of a beta-(1,4)-linked polymannose (acemannan)", page 694-B, see abstract --- -/-	1-66
Category ^o	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³									
X	Int. Conf. AIDS, vol. 6; no. 2, 1990, M.C. KEMP et al.: "Concentration-dependent inhibition of AIDS virus replication and pathogenesis by acemannan in vitro", page 315, abstract no. 1007, see abstract ---	1-66									
X	Dissertation Abstracts International, vol. 52, no. 2, August 1991, A.D. CHINNAH et al.: "Evaluation of the antiviral, adjuvant and immunomodulatory effects of a beta-(1,4)-linked polymannose (acemannan)", page 694-B, see abstract --- -/-	1-66									
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>^o Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>											
IV. CERTIFICATION <table border="1" style="width: 100%;"> <tr> <td style="width: 50%;"> Date of the Actual Completion of the International Search <div style="text-align: center;">07-07-1992</div> </td> <td style="width: 50%;"> Date of Mailing of this International Search Report <div style="text-align: center;">03.08.92</div> </td> </tr> <tr> <td> International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div> </td> <td> Signature of Authorised Officer <div style="text-align: center;">  Name of Officer: FRANK </div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="text-align: center;">07-07-1992</div>	Date of Mailing of this International Search Report <div style="text-align: center;">03.08.92</div>	International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorised Officer <div style="text-align: center;">  Name of Officer: FRANK </div>					
Date of the Actual Completion of the International Search <div style="text-align: center;">07-07-1992</div>	Date of Mailing of this International Search Report <div style="text-align: center;">03.08.92</div>										
International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorised Officer <div style="text-align: center;">  Name of Officer: FRANK </div>										

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	International Journal of Immunopharmacology, vol. 10, no. 8, 1988, D. WOMBLE et al.: "Enhancement of allo-responsiveness of human lymphocytes by acemannan (Carrisyn TM)", pages 967-974, see abstract; pages 967-968; pages 972-973: "Discussion" ---	1-66
X	Fed. Am. Soc. Exp. Biol. J., vol. 2, no. 4, 1988, J. MEASEL et al.: "The effect of Carrisyn on the immune system", abstract no. 2239, see abstract ---	1-66
X	Antiviral Res. O., suppl. 1, 1990, M.C. KEMP et al.: "In vitro evaluation of the antiviral effects of acemannan on the replication and pathogenesis of HIV-1 and other enveloped viruses: modification of the processing of glycoprotein precursors", page 83, abstract no. 84, see abstract ---	1-66
X	Antiviral Res. O., suppl. 1, 1990, H.R. McDANIEL et al.: "Extended survival and prognostic criteria for acemannan (ACE-M) treated HIV-1 patients(pts)", page 117, abstract no. 147, see abstract ---	1-66
X	American Journal of Clinical Pathology, vol. 88, no. 4, October 1987, H.Reg. McDANIEL et al.: "A clinical pilot study using Carrisyn TM in the treatment of acquired immunodeficiency syndrome (AIDS)", page 534, see abstract ---	1-66
X	Drugs of Today, vol. 25, no. 1, January 1989, Y.W. CHIEN et al.: "AIDS and chemotherapy", pages 19-25, see page 23, paragraph 2 ---	1-66
X	Mol. Biother., vol. 3, no. 1, March 1991, M.A. SHEETS et al.: "Studies of the effect of acemannan on retrovirus infections: clinical stabilization of feline leukemia virus-infected cats", pages 41-45, see abstract; pages 41-42, 44-55 ---	1-66
X	Mol. Biother., vol. 3, no. 2, June 1991, S.Y. PENG et al.: "Decreased mortality of norman murine sarcoma in mice treated with the immunomodulator, acemannan TM", pages 79-87, see abstract; pages 79-80, 85-86 --- -/-	1-66

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	WO,A,9001253 (CARRINGTON LAB., INC.) 22 February 1990, see the whole document; claims 1-15	1-66
X	WO,A,8700052 (CARRINGTON LAB., INC.) 15 January 1987, see examples 39-43	1-66

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 91/08204

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-6, 8-22, 24-26, 28, 30-31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 55, 57, 59,
because they relate to parts of the international application that do not comply with the prescribed requirements to such
an extent that no meaningful international search can be carried out, specifically:

and 61, 63, 65.
The expression "ACETLATED MANNAN DERIVATIVE" does not make clear which substances
are meant. The search had therefore to be restricted to the compound "ACEMANNAN",
which is explicitly mentioned in the claims.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9108204
SA 54348

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 24/07/92. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A- 9001253	22-02-90	US-A- 5106616	21-04-92
		AU-A- 4319489	05-03-90
		EP-A- 0382840	22-08-90
		JP-T- 3501624	11-04-91
		US-A- 5118673	02-06-92
WO-A- 8700052	15-01-87	US-A- 4735935	05-04-88
		AU-B- 607681	14-03-91
		AU-A- 6125586	30-01-87
		EP-A, B 0227806	08-07-87
		EP-A- 0328775	23-08-89
		JP-T- 63501221	12-05-88
		OA-A- 8487	29-07-88
		US-A- 4917890	17-04-90
		US-A- 4959214	25-09-90
		US-A- 4966892	30-10-90
		US-A- 4957907	18-09-90
		US-A- 4851224	25-07-89